JP2008503368 | Silicone cross-linking |
JP4776863 | Covered product |
JP6299079 | Photo-curable resin composition and cured product for forming fine structures |
GE JUNHAO (US)
ZHANG STEVE YUN (US)
PLAVNIK MICHELLE (US)
ZHENG YANG (US)
CHENG JING (US)
KUMI AUGUSTINE TWUM (US)
US20190250428A1 | 2019-08-15 | |||
US20160313571A1 | 2016-10-27 | |||
US4681412A | 1987-07-21 | |||
US6017121A | 2000-01-25 | |||
US6174464B1 | 2001-01-16 | |||
US6224945B1 | 2001-05-01 | |||
US7261844B2 | 2007-08-28 | |||
US7368072B2 | 2008-05-06 | |||
US7556750B2 | 2009-07-07 | |||
US7560056B2 | 2009-07-14 | |||
US7584630B2 | 2009-09-08 | |||
US7641337B2 | 2010-01-05 | |||
US7999989B2 | 2011-08-16 | |||
US8158037B2 | 2012-04-17 | |||
US8697770B2 | 2014-04-15 | |||
US8741188B2 | 2014-06-03 | |||
US9052438B2 | 2015-06-09 | |||
US9097916B2 | 2015-08-04 | |||
US9377569B2 | 2016-06-28 | |||
US9465234B2 | 2016-10-11 | |||
US9904074B2 | 2018-02-27 | |||
US10197707B2 | 2019-02-05 | |||
US7605190B2 | 2009-10-20 | |||
US10324311B2 | 2019-06-18 | |||
US6719929B2 | 2004-04-13 | |||
US6367929B1 | 2002-04-09 | |||
US6822016B2 | 2004-11-23 | |||
US7858000B2 | 2010-12-28 | |||
US8147897B2 | 2012-04-03 | |||
US8409599B2 | 2013-04-02 | |||
US8557334B2 | 2013-10-15 | |||
US8529057B2 | 2013-09-10 | |||
US9505184B2 | 2016-11-29 | |||
US5070215A | 1991-12-03 | |||
US6166236A | 2000-12-26 | |||
US6867245B2 | 2005-03-15 | |||
US7214809B2 | 2007-05-08 | |||
US8415405B2 | 2013-04-09 | |||
US8475529B2 | 2013-07-02 | |||
US8614261B2 | 2013-12-24 | |||
US8658748B2 | 2014-02-25 | |||
US9097840B2 | 2015-08-04 | |||
US9103965B2 | 2015-08-11 | |||
US9217813B2 | 2015-12-22 | |||
US9315669B2 | 2016-04-19 | |||
US9475827B2 | 2016-10-25 | |||
US5760100A | 1998-06-02 | |||
US4136250A | 1979-01-23 | |||
US4153641A | 1979-05-08 | |||
US4182822A | 1980-01-08 | |||
US4189546A | 1980-02-19 | |||
US4259467A | 1981-03-31 | |||
US4260725A | 1981-04-07 | |||
US4261875A | 1981-04-14 | |||
US4343927A | 1982-08-10 | |||
US4254248A | 1981-03-03 | |||
US4355147A | 1982-10-19 | |||
US4276402A | 1981-06-30 | |||
US4327203A | 1982-04-27 | |||
US4341889A | 1982-07-27 | |||
US4486577A | 1984-12-04 | |||
US4543398A | 1985-09-24 | |||
US4605712A | 1986-08-12 | |||
US4661575A | 1987-04-28 | |||
US4684538A | 1987-08-04 | |||
US4703097A | 1987-10-27 | |||
US4833218A | 1989-05-23 | |||
US4837289A | 1989-06-06 | |||
US4954586A | 1990-09-04 | |||
US4954587A | 1990-09-04 | |||
US5010141A | 1991-04-23 | |||
US5034461A | 1991-07-23 | |||
US5070170A | 1991-12-03 | |||
US5079319A | 1992-01-07 | |||
US5039761A | 1991-08-13 | |||
US5346946A | 1994-09-13 | |||
US5358995A | 1994-10-25 | |||
US5387632A | 1995-02-07 | |||
US5416132A | 1995-05-16 | |||
US5449729A | 1995-09-12 | |||
US5451617A | 1995-09-19 | |||
US5486579A | 1996-01-23 | |||
US5962548A | 1999-10-05 | |||
US5981675A | 1999-11-09 | |||
US6039913A | 2000-03-21 | |||
US6762264B2 | 2004-07-13 | |||
US7423074B2 | 2008-09-09 | |||
US8163206B2 | 2012-04-24 | |||
US8480227B2 | 2013-07-09 | |||
US8835525B2 | 2014-09-16 | |||
US8993651B2 | 2015-03-31 | |||
US9187601B2 | 2015-11-17 | |||
US10081697B2 | 2018-09-25 | |||
US10301451B2 | 2019-05-28 | |||
US10465047B2 | 2019-11-05 | |||
EP0632329A1 | 1995-01-04 | |||
US20180081197A1 | 2018-03-22 | |||
US4929693A | 1990-05-29 | |||
US5166345A | 1992-11-24 | |||
US6019914A | 2000-02-01 | |||
US6113814A | 2000-09-05 | |||
US6149841A | 2000-11-21 | |||
US6296785B1 | 2001-10-02 | |||
US6348604B1 | 2002-02-19 | |||
US3100778A | 1963-08-13 | |||
US3562172A | 1971-02-09 | |||
US3567605A | 1971-03-02 | |||
US3578602A | 1971-05-11 | |||
US3671543A | 1972-06-20 | |||
US4215010A | 1980-07-29 | |||
US4342668A | 1982-08-03 | |||
US4440672A | 1984-04-03 | |||
US4634767A | 1987-01-06 | |||
US4636561A | 1987-01-13 | |||
US4637698A | 1987-01-20 | |||
US4699473A | 1987-10-13 | |||
US4719296A | 1988-01-12 | |||
US4720547A | 1988-01-19 | |||
US4772700A | 1988-09-20 | |||
US4784474A | 1988-11-15 | |||
US4785097A | 1988-11-15 | |||
US4816584A | 1989-03-28 | |||
US4818096A | 1989-04-04 | |||
US4826977A | 1989-05-02 | |||
US4831142A | 1989-05-16 | |||
US4880667A | 1989-11-14 | |||
US4931219A | 1990-06-05 | |||
US4931221A | 1990-06-05 | |||
US4959471A | 1990-09-25 | |||
US4980089A | 1990-12-25 | |||
US4986934A | 1991-01-22 | |||
US5055576A | 1991-10-08 | |||
US5066818A | 1991-11-19 | |||
US5110922A | 1992-05-05 | |||
US5114621A | 1992-05-19 | |||
US5139707A | 1992-08-18 | |||
US5171636A | 1992-12-15 | |||
US5180524A | 1993-01-19 | |||
US5186867A | 1993-02-16 | |||
US5200116A | 1993-04-06 | |||
US5238931A | 1993-08-24 | |||
US5238981A | 1993-08-24 | |||
US5244602A | 1993-09-14 | |||
US5274132A | 1993-12-28 | |||
US5340857A | 1994-08-23 | |||
US5369158A | 1994-11-29 | |||
US5384077A | 1995-01-24 | |||
US5395567A | 1995-03-07 | |||
US5399687A | 1995-03-21 | |||
US5405958A | 1995-04-11 | |||
US5411679A | 1995-05-02 | |||
US5429774A | 1995-07-04 | |||
US5451344A | 1995-09-19 | |||
US5458814A | 1995-10-17 | |||
US5458815A | 1995-10-17 | |||
US5464567A | 1995-11-07 | |||
US5466398A | 1995-11-14 | |||
US5514817A | 1996-05-07 | |||
US5520853A | 1996-05-28 | |||
US5552090A | 1996-09-03 | |||
US5552091A | 1996-09-03 | |||
US5565147A | 1996-10-15 | |||
US5573712A | 1996-11-12 | |||
US5578252A | 1996-11-26 | |||
US5585042A | 1996-12-17 | |||
US5623005A | 1997-04-22 | |||
US5637262A | 1997-06-10 | |||
US5637709A | 1997-06-10 | |||
US5645767A | 1997-07-08 | |||
US5650098A | 1997-07-22 | |||
US5651923A | 1997-07-29 | |||
US5656206A | 1997-08-12 | |||
US5658500A | 1997-08-19 | |||
US5658501A | 1997-08-19 | |||
US5674432A | 1997-10-07 | |||
US5698141A | 1997-12-16 | |||
US5723072A | 1998-03-03 | |||
US5728758A | 1998-03-17 | |||
US5730908A | 1998-03-24 | |||
US5744070A | 1998-04-28 | |||
US5759450A | 1998-06-02 | |||
US5783116A | 1998-07-21 | |||
US5801243A | 1998-09-01 | |||
US5808063A | 1998-09-15 | |||
US5811034A | 1998-09-22 | |||
US5831090A | 1998-11-03 | |||
US5833885A | 1998-11-10 | |||
US5869658A | 1999-02-09 | |||
US5879592A | 1999-03-09 | |||
US5891368A | 1999-04-06 | |||
US5955520A | 1999-09-21 | |||
US5961892A | 1999-10-05 | |||
US5981634A | 1999-11-09 | |||
US5998520A | 1999-12-07 | |||
US6004486A | 1999-12-21 | |||
US6018059A | 2000-01-25 | |||
US6022495A | 2000-02-08 | |||
US6022497A | 2000-02-08 | |||
US6030555A | 2000-02-29 | |||
US6034193A | 2000-03-07 | |||
US6065836A | 2000-05-23 | |||
US6106744A | 2000-08-22 | |||
US6107395A | 2000-08-22 | |||
US6146554A | 2000-11-14 | |||
US6153126A | 2000-11-28 | |||
US6221284B1 | 2001-04-24 | |||
US6248264B1 | 2001-06-19 | |||
US6315928B1 | 2001-11-13 | |||
US6342459B1 | 2002-01-29 | |||
US6353102B1 | 2002-03-05 | |||
US6414057B1 | 2002-07-02 | |||
US6478988B1 | 2002-11-12 | |||
US6630597B1 | 2003-10-07 | |||
US8698117B2 | 2014-04-15 | |||
US9029532B2 | 2015-05-12 | |||
US9028728B2 | 2015-05-12 | |||
US9487499B2 | 2016-11-08 | |||
US10501446B2 | 2019-12-10 | |||
US10532997B2 | 2020-01-14 | |||
US10502998B2 | 2019-12-10 | |||
US4444711A | 1984-04-24 | |||
US4460534A | 1984-07-17 | |||
US5843346A | 1998-12-01 | |||
US5894002A | 1999-04-13 | |||
US6451871B1 | 2002-09-17 | |||
US6793973B2 | 2004-09-21 | |||
US6811805B2 | 2004-11-02 | |||
US6896926B2 | 2005-05-24 | |||
US4312575A | 1982-01-26 | |||
US4632844A | 1986-12-30 |
P. BAMFIELD: "Chromic Phenomena: Technological Applications of Colour Chemistry", 2001, RSC BOOKS
What is claimed is: 1. A method for producing hydrogel contact lenses, comprising the steps of: (1) obtain a first polymerizable fluid composition and a second polymerizable fluid composition, wherein the first polymerizable fluid composition comprises at least one first free-radical initiator, at least one first polymerizable material, and at least one photochromic compound, wherein said at least one first polymerizable material comprises at least one first polysiloxane vinylic crosslinker that has a weight-averaged molecular weight of about 5000 Daltons or higher and is present in the first polymerizable composition in an amount of about 40% by weight or more, wherein the second polymerizable fluid composition comprises said at least one second free-radical initiator and at least one second polymerizable material and is free of any photochromic compound; (2) obtaining a lens mold, wherein the lens mold comprises a male mold half having a first molding surface defining the posterior surface of a contact lens to be molded and a female mold half having a second molding surface defining the anterior surface of the contact lens to be molded, wherein the female and male mold halves are configured to receive each other such that a mold cavity is formed between the first and second molding surfaces when the mold is closed; (3) applying a drop of the first polymerizable fluid composition onto the geometrial center of the first molding of the male mold half, wherein the drop has a volume of about 5µL or less; (4) dispensing an amount of the second polymerizable fluid composition on the second molding surface of the female mold half; (5) closing the female mold half with the male mold half having the drop adhered thereon to form a molding assembly comprising the second polymerizable composition and the drop of the first polymerizable composition within the mold cavity; (6) curing the second polymerizable fluid composition and the drop of the first polymerizable composition to form an unprocessed silicone hydrogel contact lens having a central photochromic zone that has a diameter of about 13 mm or less, is concentric with the central axis of the unprocessed silicone hydrogel contact lens; (7) separating the molding assembly into the male and female mold halves, with the unprocessed silicone hydrogel contact lens adhered onto a lens-adhered mold half which is one of the male and female mold halves; (8) removing the unprocessed silicone hydrogel contact lens from the lens-adhered mold half; and (9) subjecting the unprocessed silicone hydrogel contact lens to post-molding processes including a hydration process and one or more other processes selected from the group consisting of extraction, surface treatment, packaging, sterilization, and combinations thereof. 2. The method of claim 1, wherein the step of (6) curing is carried out thermally, wherein said at least one first and second free-radical initiators comprise a thermal free-radical initiator. 3. The method of claim 1, wherein the step of (6) curing is carried out actinically, wherein said at least one first and second free-radical initiators comprise a free-radical photoinitiator. 4. The method of any one of claims 1 to 3, wherein the first polymerizable fluid composition further comprises at least one visible light free-radical photoinitiator, wherein the drop of the first polymerizable fluid composition is irradiated with a visible light for about 10 second or less before dispensing the second polymerizable fluid composition. 5. The method of any one of claims 1 to 4, wherein said at least one first and second polymerizable materials independent of each other comprises: (a) at least one silicone- containing vinylic monomer, (b) at least one second polysiloxane vinylic crosslinker, at least one non-silicone vinylic crosslinker, or combinations thereof, (c) at least one hydrophilic vinylic monomer, and optionally (d) at least one component selected from the group consisting of a non-silicone hydrophobic vinylic monomer, a UV-absorbing vinylic monomer, and combinations thereof, wherein said at least one hydrophilic vinylic monomer comprises: (i) at least one hydrophilic (meth)acrylamido monomer having 3 to 8 carbon atoms; (ii) at least one hydrophilic (meth)acryloxy monomer; (iii) at least one hydrophilic N-vinyl amide monomer; or (iv) combinations thereof. wherein said at least one silicone-containing vinylic monomer comprises: (i) at least one silicone-containing vinylic monomer containing a tris(trialkylsiloxy)silyl group and one sole ethylenically-unsaturated group selected from the group consisting of a (meth)acryloyloxy group, a (meth)acryloylamino group, a vinyl carbonate group, and a vinylcarbamate group; (ii) at least one silicone-containing vinylic monomer containing a bis(trialkylsilyloxy)-alkylsilyl group and one sole ethylenically-unsaturated group selected from the group consisting of a (meth)acryloyloxy group, a (meth)acryloylamino group, a vinyl carbonate group, and a vinylcarbamate group; (iii) at least silicone- containing vinylic monomer containing a) one sole ethylenically-unsaturated group selected from the group consisting of a (meth)acryloyloxy group, a (meth)acryloylamino group, a vinyl carbonate group, and a vinylcarbamate group and b) a polysiloxane chain having 2 to 30 siloxane units and terminated with an alkyl, hydroxyalkyl or methoxyalkyl group; or (iv) combinations thereof. 6. The method of claim 5, wherein the sum of the amounts of components (a), (b) and (c) in the monomer mixture is at least about 60% by weight relative to the total weight of all polymerizable materials present in the monomer mixture. 7. The method of claim 5 or 6, wherein said at least one first and second polymerizable materials independent of each other comprise at least one second polysiloxane vinylic crosslinker. 8. The method of any one of claims 1 to 7, wherein said at least one first and second polymerizable materials independent of each other comprises: at least one non-silicone vinylic crosslinker; at least one non-silicone hydrophobic vinylic monomer; at least one UV-aborbing vinylic monomer; or combinations thereof. 9. The method of any one of claims 1 to 8, wherein said at least one photochromic compound comprises a naphthopyran, an indeno-fused naphthopyran (i.e., indeno- naphthopyran), a heterocyclic ring-fused naphthopyrian, a benzopyran, a phenanthropyran, a quinopyran, a quinolinopyran, a fluoroanthenopyran, an anthracene-fused pyran, a tetracene-fused pyran, a spiro(benzindoline) naphthopyran, a spiro(indoline)naphthopyran, a spiro(indoline)benzopyran, a spiro(indoline)quinopyran, a spiro(indoline)pyran, a naphthoxazine, a spirobenzopyran, a spirobenzothiopyran, a naphthacenedione, a benzoxazine, a spirooxazine, a naphthoxazine, a spiro(benzindoline)naphthoxazine, a spiro(indoline)naphthoxazine, a spiro(indoline)pyrido-benzoxazine, a spiro(indoline)benzoxazine, a spiro(benzindoline) benzoxazine, a spiro(benzindoline)pyridobenzoxazine, a spiro(indoline) fluoranthenoxazine, a spiro(indoline)-quinoxazine, a spiropiperidine-naphthopyran, a piro(indoline)pyronobenzoxazinone, a benzospiropyran, a naphthospiropyran, a spirobenzoxazine-pyrrolopyridine, a spironaphthoxazine-pyrrolopyrridine, a spiro- oxazepin-benzoxazine, a spiro-oxazepin-naphthoxazine, a spiro(indoline) benzothiazoloxazine, a spiro(indoline)benzopyrroloxazine, a spiro(indoline)quinazolino- oxazine, a spiro(indoline)-anthracenobenzoxazine, a benzofurobenzopyran, a benzothienobenzopyran, a naphthofurobenzopyran, a benzopyrano-fused naphthopyran, a spiro(isoindoline)-naphthoxazine, a spiro(isoindoline)benzoxazine, or a mixture thereof. 10. The method of any one of claims 1 to 9, wherein said at least one photochromic compound is polymerizable (i.e., comprising an ethylenicaly-unsaturated group). 11. The method of claim 10, wherein said at least one photochromic compound is a coupling reaction product of a reactive (meth)acrylamido or (meth)acryloxy monomer having a first reactive functional group and a reactive photochromic compound have a second reactive functional group in the absence or presence of a coupling agent under coupling reaction, wherein the first reactive functional group is selected from the group consistin ; wherein the second reactive functional group is selected from the group consisting wherein R0 is hydrogen or methyl and RN2 is hydrogen, a linear or branched C1-C15 alkyl, cyclohexyl, cyclopentyl, a substituted or unsubstituted phenyl, or a substituted- or unsubstituted-phenyl-C1-C6 alkyl. 12. The method of claim 11, wherein the reactive (meth)acrylamido or (meth)acryloxy monomer is selected from the group consisting of (meth)acryloyl halides (CH2=CH─COX or CH2=CCH3─COX, X= Cl or Br), N-hydroxysuccinimide ester of (meth)acrylic acid, glycidyl (meth)acrylate, isocyanato- C2-C6 alkyl (meth)acrylate, amino–C2-C6 alkyl (meth)acrylamide, C1-C6 alkylamino–C2-C6 alkyl (meth)acrylamide, (meth)acrylic acid, C2-C4 alkylacrylic acid (e.g., ethylacrylic acid, propylacrylic acid, butylacrylic acid), N-2-acrylamidoglycolic acid, 3-(acryloylxy)propanoic acid, C2-C6 hydroxylalkyl (meth)acrylate, C2-C6 hydroxyalkyl (meth)acrylamide, azlactone-containing vinylic monomers (e.g., 2-vinyl-4,4-dimethyl-1,3-oxazolin-5-one, 2-isopropenyl-4,4- dimethyl-1,3-oxazolin-5-one, 2-vinyl-4-methyl-4-ethyl-1,3-oxazolin-5-one, 2-isopropenyl- 4-methyl-4-butyl-1,3-oxazolin-5-one, 2-vinyl-4,4-dibutyl-1,3-oxazolin-5-one, 2- isopropenyl-4-methyl-4-dodecyl-1,3-oxazolin-5-one, 2-isopropenyl-4,4-diphenyl-1,3- oxazolin-5-one, 2-isopropenyl-4,4-pentamethylene-1,3-oxazolin-5-one, 2-isopropenyl- 4,4-tetramethylene-1,3-oxazolin-5-one, 2-vinyl-4,4-diethyl-1,3-oxazolin-5-one, 2-vinyl-4- methyl-4-nonyl-1,3-oxazolin-5-one, 2-isopropenyl-4-methyl-4-phenyl-1,3-oxazolin-5-one, 2-isopropenyl-4-methyl-4-benzyl-1,3-oxazolin-5-one, 2-vinyl-4,4-pentamethylene-1,3- oxazolin-5-one, and 2-vinyl-4,4-dimethyl-1,3-oxazolin-6-one, with 2-vinyl-4,4-dimethyl- 1,3-oxazolin-5-one (VDMO) and 2-isopropenyl-4,4-dimethyl-1,3-oxazolin-5-one (IPDMO) as preferred azlactone-containing vinylic monomers), aziridinyl C1-C12 alkyl (meth)acrylate (e.g., 2-(1-aziridinyl) ethyl (meth)acrylate, 3-(1-aziridinyl) propyl (meth)acrylate, 4-(1-aziridinyl) butyl (meth)acrylate, 6-(1-aziridinyl) hexyl (meth)acrylate, or 8-(1-aziridinyl) octyl (meth)acrylate), acrolein, methacrolein, crotonaldehyde, and combinations thereof. 13. The method of claim 11 or 12, wherein the reactive photochromic compound comprises 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxyethoxy-13-phenyl-3H,13H-indeno [2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-(2- hydroxycarbonylethyl)carboxyethoxy-13-phenyl-3H,13H-indeno [2’,3’:3,4]naphtho[1,2- b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-phenyl-3H,13H-indeno [2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-(2- hydroxycarbonylethyl)carboxy-13-phenyl-3H,13H-indeno [2’,3’:3,4] naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-propyl-3H,13H- indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-(2- hydroxycarbonylethyl)carboxy-13-propyl-3H,13H-indeno[2’,3’:3,4]-naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-10,11-dimethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1- f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-10,11-dimethoxy-13-(2- hydroxycarbonylethyl)carboxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3- bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-hydroxymethyl-13-methyl-3H,13H- indeno[2’,3’:3,4] naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-7-methoxy-11-phenyl- 13-(2-hydroxycarbonylethyl)carboxymethyl-13-methyl-3H,13H-indeno[2’,3’:3,4]- naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-hydroxy-13- methyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-7- methoxy-11-phenyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H,13H-indeno- [2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-11-phenyl-13-hydroxy-13- methyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-11- phenyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H,13H-indeno[2’,3’:3,4]- naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7,10,11-tetramethoxy-13-hydroxy-13- ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,7,10,11- tetramethyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H,13H-indeno[2’,3’:3,4]- naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-13-hydroxy-13-ethyl- 3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-11-(4-(4,5- diphenyl-1H-imidazol-2-yl)phenyl-13,13-dimethyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2- b]pyran; 3,3-di(4-methoxyphenyl)-6-methoxy-7-(3-hydroxymethylenepiperidin-1-yl)- 13,13-dimethyl-3H,13H-indeno[2’,3':3,4]naphtho[1.2-b]pyran; 3,3-di(4-methoxyphenyl)- 6-methoxy-7-(3-(2-hydroxycarbonylethyl)-carboxymethylenepiperidin-1-yl)-13,13- dimethyl-3H,13H-indeno[2’,3':3,4]naphtho[1.2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7- dimethoxy-13-hydroxy-13-butyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4- methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-hydroxyethoxy)-ethoxy)-indeno[2,1- f]naptho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-(2-(2- hydroxyethoxy)ethoxy)ethoxy)ethoxy)-indeno[2,1-f]naptho[1,2-b]pyran; 3,3-diphenyl-13- hydroxy-13-(2-oxo-2-ethoxyethyl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4- methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-(2-oxo-2-ethoxyethyl)-1H-indeno[2,1- f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,11-dimethyl-13-butyl-13-hydroxy- indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-hydroxyphenyl)-7-methoxy-11-phenyl-13,13- diethyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-hydroxyphenyl)-7- methoxy-11-phenyl-13,13-dipropyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3,3- bis(4-hydroxyphenyl)-7-methoxy-11-phenyl-13-carbomethoxy-13-methyl-3H,13H- indeno[2’,3’:3,4] naphtho[1,2-b]pyran; 3,3-diphenyl-6,7-dimethoxy-13-methyl-13-methyl- 13-hydroxyethoxy-ethoxyethoxy-3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3,3- diphenyl-6,7,10,11-tetramethoxy-13-ethyl-13-methyl-13-hydroxyethoxyethoxy-3H,13H- indeno[2’,3’:3,4]naphtho [1,2-b]pyran; 6,7-dimthoxy-2,2-diphenyl-13-hydroxy-13-butyl- 2H,13H-indeno[1’,2’:4,3] naphtho[1,2-b]pyran; 6,7-dimthoxy-2,2-diphenyl-13-hydroxy- 13-methyl-2H,13H-indeno[1’,2’:4,3]naphtho[1,2-b]pyran; 6,7-dimthoxy-2,2-diphenyl-13- hydroxy-2H,13H-indeno[1’,2’:4,3]naphtho[1,2-b]pyran; 3-(4-allyloxyphenyl)-3-(4- morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethy-3H,13H- indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10- (piperazin-1-yl)-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2’,3’:3:4]naphtho[1,2- b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10-(4-hydroxybenzamido)-6- trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2’,3’:3:4]naphtho[1,2-b]pyran; 3-(4- fluorophenyl)-3-(4-butoxyphenyl)-10-vinyl-6-trifluoromethyl-13,13-dimethyl-3H,13H- indeno[2’,3’:3:4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10- (carboxylic acid)-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2’,3’:3:4]naphtho[1,2- b]pyran; 3-(4-fluorophenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)- 13,13-dimethyl-3H,13H-indeno[2',3’:3,4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4- methoxyphenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl) carboxypiperidin-1-yl)-13,13- dimethyl-3H,13H-indeno[2',3’:3,4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4- morpholinophenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H- indeno[2',3’:3,4]naphtho[1.2-b]pyran; 3-(4-fluorophenyl)-3-(4-morpholinophenyl)-6- methoxy-7-(4-(2-hydroxycarbonylethyl) carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H- indeno[2',3’:3,4] naphtho[1.2-b]pyran; 3-(4-hydroxyethoxyphenyl)-3-(4-methoxyphenyl)- 11-(4-(N,N-dimethylamino)phenyl)-13,13-dimethyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2- b]pyran; 3-(4-methoxyphenyl)-3-(2,4-dimethoxyphenyl)-phenyl-6,11-dimethoxy-13- methyl-13-methyl-13-hydroxyethoxyethoxyethoxy-3H,13H-indeno[2’,3’:3,4]naphtho[1,2- b]pyran; 3-(4-methoxyphenyl)-3-(3-methyl-4-methoxyphenyl)-13-hydroxy-indeno[2,1- f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-6,7,10,11- tetramethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4- methoxyphenyl)-3-(4-morpholinophenyl)-6,7,10,11-tetramethoxy-13-hydroxy-13-butyl- 3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)- 6,7-dimethoxy-13-hydroxy-13-ethyl-3H,13H-indeno [2,1-f]naphtho[1,2-b]pyran; 3-(4- methoxyphenyl)-3-(4-morpholinophenyl)-6,7-dimethoxy-13-hydroxy-13-methyl-3H,13H- indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-13-oxo- 3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-phenyl-6-methoxy-7- mprphlino-13-methyl-13-methyl-13-hydroxyethoxyethoxyethoxy-3H,13H- indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-phenyl-6,11-dimethoxy-13- methyl-13-methyl-13-hydroxyethoxy-ethoxy-3H,13H-indeno[2’,3’:3,4]naphtho[1,2- b]pyran; 2-(4-methoxyphenyl)-2-(4-morpholinophenyl)-5-hydroxy-6-carboethoxy-2H- naphtho[1,2-b] pyran; 3-(4-morpholinophenyl)-3-phenyl-6,7-dimethoxy-13-hydroxy-13- ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-morpholinophenyl)-3-phenyl-6,7- dimethoxy-13-hydroxy-13-butyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4- morpholinophenyl)-3-phenyl-6,7-dimethoxy-13-oxo-3H,13H-indeno[2,1-f]naphtho[1,2- b]pyran; 3-phenyl-3-(4-hydroxyethoxyphenyl)-6-methoxy-7-morpholino-13,13-dimethyl- 3H,13H-indeno-[2',3’:3,4] naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2- hydroxycarbonylethyl)carboxyethoxy-phenyl)-6-methoxy-7-morpholino-13,13-dimethyl- 3H,13H-indeno[2',3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxyethoxy)phenyl)- 6-methoxy-7-piperidino-13,13-dimethy-3H,13H-indene[2’,3’:3,4]naphtho[1,2-b]pyran; 3- phenyl-3-(4-(2-(2-hydroxycarbonylethyl)-carboxyethoxy)phenyl)-6-methoxy-7-piperidino- 13,13-dimethy-3H,13H-indene[2’,3’:3,4] naphtho[1,2-b]pyran; 3-phenyl-3-(4- hydroxyphenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2’,3’:3,4]naphtho[I,2- b]pyran; 3-phenyl-3-(4-hydroxyethoxy)phenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H- indeno[2’,3’:3,4]-naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2- hydroxycarbonylethyl)carboxyethoxy)phenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H- indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxycarbonylethyl)carboxy- phenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2’,3’:3,4]naphtho[I,2-b]pyran; 3- phenyl-3-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-13,13-dimethyl-3H,13H- indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-(2-(2-hydroxycarbonylethyl)- carboxyethyl)piperazin-1-yl)phenyl)-13,13-dimethyl-3H,13H-indeno[2’,3’:3,4]naphtho- [1,2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-piperazinyl-13,13-dimethyl- 3H,13H-indene[2’,3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy- 7-(3-hydroxymethylenepiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno [2’,3”:3.4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(3-(2- hydroxycarbonylethyl) carboxymethylenepiperidin-1-yl)-13,13-dimethyl-3H,13H- indeno[2’,3”:3.4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(4- hydroxypipendin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho-[1,2-b]pyran; 3- phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl)-carboxypipendin- 1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4- methoxyphenyl-piperazin-1-yl)phenyl)-13,13-dimethyl-6-methoxy-7-hydroxy-indeno [2’,3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-methoxyphenyl-piperazin-1-yl)phenyl)- 13,13-dimethyl-6-methoxy-7-(2-hydroxy-2-methyl-3-butyn-4-yl)-indeno[2’,3’:3,4]naphtho [1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(3-hydroxymethylene- piperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3’:3,4]naphtho-[1,2-b]pyran; 3-phenyl-3- (4-morpholinophenyl)-6-methoxy-7-(3-(2-hydroxycarbonyl-ethyl)carboxymethylene- piperidin-1-yl)-13,13-dimethyl-3H,13H-indeno [2’,3’:3.4]-naphtho[1,2-b]pyran; 3-phenyl- 3-(4-morpholinophenyl)-6-methoxy-7-(3-(2-hydroxycarbonylethyl)carboxymethylene- piperidin-1-yl)-13,13-dimethyl-3H,13H-indeno [2',3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3- (4-morpholinophenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H- indeno[2’,3’:3,4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(4- (2-hydroxycarbonylethyl)-carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2’,3’:3,4] naphtho[1.2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-piperazinyl-13,13- dimethyl-3H,13H-indeno[2’,3’:3,4]naphtho [1.2-b]pyran; 3-phenyl-3-(4- morpholinophenyl)-6,11-dimethyl-13-hydroxy-13-(1-oxo-methoxyprop-2-yl)-1H- indeno[2,1-f]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-phenylpiperazino)-phenyl)-6- methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2’,3':3,4] naphtho[1.2-b]pyran; 3-phenyl-3-(4-(4-phenylpiperazino)phenyl)-6-methoxy-7-(4-(2- hydroxycarbonylethyl) carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2’,3':3,4] naphtho[1.2-b]pyran; 3-phenyl-3-(4-piperazinylphenyl)-6,11-dimethoxy-13,13-dimethyl- 3H,13H-indeno[2’,3’:3,4]naphtho-[1,2-b]pyran; 3-phenyl-3-(4-piperazinylphenyl)-6- methoxy-7-piperidinyl-13,13-dimethyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3- phenyl-3-(4-(3-methylpiperazin-1-yl)phenyl)-6-methoxy-7-(decahydroisoquinolin-2-yl)- 11-tert-butyl-13,13-dimethyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-(4- methoxyphenyl)-3-(4-morpholinophenyl)-16-(ethoxycarnobyl)methyl-16-hydroxy-3,16- dihydrobenzofuro-[2’,3’:7,8] indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4- methoxyphenyl)-16-(ethoxycarnobyl)-methyl-16-hydroxy-3,16-dihydrobenzofuro [2”,3”:6’,7’]indeno-[3’,2’:4,3]naphtho[1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-16- (ethoxycarnobyl)-methyl-16-hydroxy-3,16-dihydrobenzofuro[2”,3”:6’,7’]indeno[3’,2’:4,3] naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-(ethoxycarbonyl)methyl-16-hydroxy- 3,16-dihydro-benzofuro[2’,3’:7,8]indeno[2’,3’:3,4] naphtho[1,2-b]pyran; 3,3-di(4- methoxyphenyl)-16-hydroxy-16-ethyl-16H-benzofuro[2’,3’:7,8] indeno[2’,3’:3,4]naphtho [1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-hydroxy-16H-benzofuro [2”,3”:6,7]indeno [3’,2’:4,3]naphtho-[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-hydroxy-16-ethyl-16H- benzofuro[2”,3”:6,7]-indeno[3’,2’:4,3]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(2,3- diydrobenzofur-5-yl)-13-hydroxy-13-methyl-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4- methoxyphenyl)-3-(2,3-dihydrobenzofur-5-yl)-6,11-difluoro-13-hydroxy-13-(1-oxo- methoxyprop-2-yl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran, or a mixture thereof. 14. The method of claim 11 or 12, wherein the reactive photochromic compound is 2,2-di(4- fluorophenyl)-5-hydroxycarbonyl-6-phenyl-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2- bis(4-methylphenyl)-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4- methoxyphenyl)-5-methoxycarbonyl-6-hydroxy-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4- methoxyphenyl)-5-methoxyethoxycarbonyl-6-methyl-8-vinyl-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxyethoxycarbonyl-6-methyl-8-hydroxycarbonyl-2H- naphtho [1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxycarbonyl-6-(2- hydroxyethoxy)ethoxy-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5- methoxycarbonyl-6-phenyl-9-(2-hydroxyethoxy)-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4- methoxyphenyl)-5-methoxy-carbonyl-6-(4-(2-hydroxyethoxy)phenyl)-[2H]-naphtho[1,2- b]pyran; 2,2-bis(4-methoxyphenyl)-5-diphenylmethylol-6-hydroxy-2H-naphtho[1,2- b]pyran; 2,2-bis(4-methoxyphenyl)-5-diphenylmethylol-6-methoxy-2H-naphtho[1,2- b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-hydroxyethoxylcarbonyl)-6-phenyl-[2H]- naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-(2-hydroxyethoxy)-ethoxycarbonyl)- 6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-(2-(2- hydroxyethoxy)ethoxy)-ethoxycarbonyl)-6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4- methoxyphenyl)-5-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)-ethoxycarbonyl)-6-phenyl- [2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-methyl-9- methoxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-phenyl- 2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-methoxy-2H- naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxycarbonyl-6-(3-aminophenyl)- 2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-2,5,7-trihydro-7-methylidine-5-oxo- furo-[3’,4’:3,4]naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-phenylthio-6-hydroxy- 2H-naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-13-hydroxy-13-methyl-indeno[2,1- f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-9-methoxycarbonyl-8-(2- hydroxyethoxy)ethoxy-[3H]-naptho[1,2-b]pyran; 2,2-diphenyl-5-hydroxycarbonyl-9- methoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxycarbonyl-8,9-dimethoxy-2H- naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-morpholinocarbonyl-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5- hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6- carbomethoxy-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6- morpholinocarbonyl-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-methylol-6-(3- dimethylaminopropyl)methylamino-2H-naphtho[1,2-b]pyran;2,2-diphenyl-2,5,7-trihydro- 7-methyliden-5-oxofuro-[3’,4’:3,4]naphtho[1,2-b]pyran; 2,2-spiroadamantylene-5- phenylthio-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl)-5-methoxycarbonyl-6- hydroxy-2H-naphtho[1,2-b]pyran; 2,2-spiro-admamtylene-5-methoxycarbonyl-6- hydroxy-2H-naphtho[1,2-b]pyran, 3,3-diphenyl-8-hydroxy-9-carbopropoxy-3H- naphtho[2,1-b]pyran; 2,2,5-triphenyl-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2,2,6- triphenyl-5-(2-(2-(2-(2-hydroxyethoxy)ethoxy)-ethoxy)ethoxy)carbonyl-[2H]-naphtho[1,2- b]pyran; 2,2,6-triphenyl-5-(2-(2-(2-oxiran-2-ylmethoxy)ethoxy)ethoxy)-ethoxycarbonyl)- [2H]-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-(4-morpholinophenyl)-5-hydroxy-6- carboethoxy-2H-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-tert-butyl-5-methoxy- carbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-phenyl-5- methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(4-(2-(2-hydroxyethoxy)ethoxy)- ethoxyphenyl)-2-phenyl-5-methoxycarbonyl-6-methyl-9-methoxy-[2H]-naphtho[1,2- b]pyran; 2-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)- 2-phenyl-5-methoxycarbonyl-6-(2-(2- methylprop-2-enoxyloxy)ethoxy)-[2H]-naphtho[1,2-b]pyran; 3-(4-(2-(2-hydroxyethoxy)- ethoxy)ethoxyphenyl)-3-phenyl-9-methoxycarbonyl-8-methoxy-[3H]-naptho[1,2-b]pyran; 2-(4-morpholinophenyl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H-naphtho[1,2- b]pyran; 2-(9-ethylcarbazol-2-yl)-2-phenyl-5-methoxycarbonyl-6-hydroxy-2H- naphtho[1,2-b]pyran; 2-(9-phenylcarbazol-2-yl)-2-phenyl-5-methoxycarbonyl-6-hydroxy- 2H-naphtho[1,2-b]pyran; 2-(4-dimethylaminophenyl)-2-phenyl-5-methoxycarbonyl-6- hydroxy-2H-naphtho[1,2-b]pyran; 3-(2-flurophenyl)-3-(4-methoxyphenyl-8-hydroxy-9- carbopropoxy-3H-naphtho[2,1-b]pyran; 3-(2-flurophenyl)-3-(4-methoxyphenyl-8- hydroxy-9-carbomethoxy-3H-naphtho[2,1-b]pyran; 3-(2,4-dimethoxyphenyl)-3-(4- methoxyphenyl-8-hydroxy-9-carbomethoxy-3H-naphtho[2,1-b]pyran; 3-(2,4,6- triflurophenyl)-3-(2,4,6-trimethoxy-1-naphthyl)-8-acetyl-9-carboniloyl-3H-naphtho[2,1- b]pyran; 3-(4-methoxyphenyl)-3-(2-methyl-2,3-dihydrobenzofur-5-yl)-6-methoxy-12- hydroxymethyl-11-phenyl-3H-phenanthro[1,2-b]pyran; 5,5-bis(4-methoxyphenyl)-8- methylol-5H-fluorantheno[3,2-b]pyran; or a mixture thereof. 15. The method of claim 11 or 12, wherein the reactive photochromic compound is 1- hydroxyethyl-3,3-dimethylspiro[indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 1- hydroxypropyl-3,3-dimethylspiro[indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 1- aminoethyl-3,3-dimethyl-5-chlorospiro[indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 1- hydroxyethyl-3,3-dimethyl-8’-methoxyspiro[indoline-2,3’-[3H]-naphtho[2,1- b][1,4]oxazine]; 1-(p-vinylphenyl)-3,3-dimethyl-5,6-dichlorospiro[indoline-2,3’-[3H]- naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-9’-hydroxyspiro[indoline-2,3’-[3H]- naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-5’-hydroxymethylspiro[indoline-2,3’-[3H]- naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-9’-aminospiro[indoline-2,3’-[3H]- naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-5-chloro-8’-hydroxyspiro[indoline-2,3’-[3H]- naphtho[2,1-b][1,4]oxazine]; 1-benzyl-3,3-dimethyl-9’-vinylbenzoyloxyspiro[indoline-2,3’- [3H]-naphtho[2,1-b][1,4]oxazine]; 1-benzyl-3,3-dimethyl-5’- hydroxymethylpiperidinospironaphthooxazine; 1,3,3-trimethyl-9’-hydroxyspiro[indoline- 2,3’-[3H]-pyrido-[2,1-b][1,4]benzooxazine]; 5-hydroxy-6’-cyano-1,3,3-trimethyl-spiro- [indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 5-hydroxy-6’-phenylsulfonyl-1,3,3- trimethyl-spiro-[indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 5’formyl-1,3,3- trimethylspiro[indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine; 1,3-dihydro-6’-piperazino- 1,3,3-trimethyl spiro [2H indole-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine; 1,3-dihydro-6’-(4- hydroxyethyl)piperazino-1,3,3-trimethyl spiro [2H indole-2,3’-[3H]-naphtho[2,1- b][1,4]oxazine; 1,3-dihydro-9’-hydroxy-1,3,3-trimethyl spiro 92H indole-2,3’-[3H]- naphtho[2,1-b][1,4] oxazine; 1,3,3,4,5-pentamethyl-9’-methoxycarbonyl-8’-hydroxy- spiro[indoline-2,3’-[3H]naphth[2,1-b][1,4]oxazine; 1,3,3,5,6-pentamethyl-9’- methoxycarbonyl-8’-hydroxy-spiro[indoline-2,3’-[3H]naphth[2,1-b][1,4]oxazine; 1-propyl- 3,3,4,5-tetramethyl-9’-methoxycarbonyl-8’-hydroxy-spiro[indoline-2,3’-[3H]naphth[2,1- b][1,4]oxazine; 1-propyl-3,3,5,6-tetramethyl-9’-methoxycarbonyl-8’-hydroxy- spiro[indoline-2,3’-[3H]naphth[2,1-b][1,4]oxazine; 1-methoxyethyl-3,3-dimethyl-9’- allyloxycarbonyl-8’-chloroactoxy-spiro[indoline-2,3’-[3H]naphth[2,1-b][1,4]oxazine; 1- allyl-3,3-spirocyclohexyl-9’-benzyloxycarbonyl-8’-chloroactoxy-spiro[indoline-2,3’- [3H]naphth[2,1-b][1,4]oxazine; 5-amino-1,3,3-trimethyl-spiro[indoline-2,3’-[3H]- pyrido[3,4-f][1,4]benzoxazine; 6-hydroxy-1’,3’,3’,4’,5’-pentamethylspiro[2H-1,4- benzoxazine-2,2’-indoline]; 6-hydroxy-1’,3’,3’,5’,6’-pentamethylspiro[2H-1,4- benzoxazine-2,2’-indoline]; 5,7-dimethoxy-1’-hydroxy-carbonylethyl-3’,3’- dimethylspiro[2H-1,4-bezoxazine-2,2’-indoline]; 7-methoxy-1’-hydroxy-ethyl-3’,3’- dimethylspiro[2H-1,4-bezoxazine-2,2’-indoline]; 9’-hydroxy-1-methylspiro[indoline-2,3’- (3H)-naphtho(2,1-b)-1,4-oxazine]; 5-chloro-9’-hydroxy-1-methylspiro[indoline-2,3’-(3H)- naphtho(2,1-b)-1,4-oxazine]; 8’-hydroxy-1-methylspiro[indoline-2,3’-(3H)-naphtho(2,1- b)-1,4-oxazine]; 8’-hydroxy-5-methoxy-1-methylspiro[indoline-2,3’-(3H)-naphtho(2,1-b)- 1,4-oxazine]; 8’-hydroxy-1,4,5-trimethylspiro[indoline-2,3’-(3H)-naphtho(2,1-b)-1,4- oxazine]; 9’-hydroxy-1-isopropylspiro[indoline-2,3’-(3H)-naphtho(2,1-b)-1,4-oxazine]; 9’- hydroxy-1-hexadecyl-spiro[indoline-2,3’-(3H)-naphtho(2,1-b)-1,4-oxazine]; 9’-hydroxy-1- octadecylspiro[indoline-2,3’-(3H)-naphtho(2,1-b)-1,4-oxazine]; 1,1”-(1,5- pentanediyl)bis[3,3-dimethyl]-9’-hydroxy-spiro[indoline-2,3’-[3H]-naphtho[2,1-b] [1,4]oxazine]; 1,1”-[1,4-phenylenebis(methylene)] bis[3,3-dimethyl]-5’- hydroxymethylspiro[indoline-2,3’-[3H]-naphtho[2,1-b] [1,4]oxazine]; 1,1”-(1,4- butanediyl)bis[5,6-dichloro-3,3-dimethyl]-8’-hydroxyspiro[indoline-2,3’-[3H]-naphtho[2,1- b] [1,4]oxazine]; 1,3,3-trimethyl-9’-hydroxypiperidinospironaphthooxazine; 3- carboxyethyl-1,1-dimethyl-9’-methoxyspiro[benz[e]-indoline-2,3’-[3H]-naphtho[2,1- b][1,4]oxazine]; 1-carboxyethyl-3,3-dimethyl-9’-methoxyspiro[benz[g]-indoline-2,3’-[3H]- naphtho[2,1-b][1,4]oxazine]; 1,1-dimethyl-3-hydroxyethyl-9’-methoxyspiro[benz[e]- indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 3,3-dimethyl-1-hydroxyethyl-9’- methoxyspiro[benz[g]-indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 3-carboxyethyl-1,1- dimethyl-9’-methoxyspiro[benz[e]-indoline-2,3’-[3H]-pyrido[2,1-b][1,4]benzoxazine]; 1- carboxyethyl-3,3-dimethyl-9’-methoxyspiro[benz[g]-indoline-2,3’-[3H]-pyrido[2,1- b][1,4]benzoxazine]; 1,1-dimethyl-3-hydroxyethyl-9’-methoxyspiro[benz[e]-indoline-2,3’- [3H]-pyrido[2,1-b][1,4]benzoxazine]; 3,3-dimethyl-1-hydroxyethyl-9’- methoxyspiro[benz[g]-indoline-2,3’-[3H]-pyrido[2,1-b][1,4]benzoxazine]; 5-amino-5’-(2- benzthiazolyl)-1,3,3-trimethylspiro[indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 5- amino-5’-(5’-(2-hydroxyphenyl)-2-oxadiazolyl)-1-isopropyl-3,3-dimethylspiro[indoline- 2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 5-amino-5’-(5’-phenyl-2-oxadiazolyl)-1,3,3- trimethylspiro[indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; or a mixture thereof. 16. The method of claim 11 or 12, wherein the reactive photochromic compound is 3,3- bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxyethoxy-13-phenyl-3H,13H-indeno [2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-(2- hydroxycarbonylethyl)carboxyethoxy-13-phenyl-3H,13H-indeno [2’,3’:3,4]naphtho[1,2- b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-phenyl-3H,13H-indeno [2’,3’:3,4]naphtho[1,2-b]pyran; or a mixture thereof. 17. The method of any one of claims 1 to 16, wherein said at least one first and second polymerizable materials independent of each other comprises at least one polymerizable UV/HEVL-absorbing compound. 18. A hydrogel contact lens obtained according to the method of any one of claims 1 to 17. |
is C 1 -C 4 alkyl, and f1 is an integer of from 3 to 5. 28. The method of any one of embodiments 13 to 27, wherein said at least one silicone- containing vinylic monomer comprises at least one mono-(meth)acrylamido-terminated oligo- or polysiloxane of formula (IIa) in which R’ is hydrogen or methyl, R” independent of each other is C 1 -C 6 alkyl, g1 and g2 independent of each other are integer of 0 or 1, h1 is an integer of 2 to 25, R 9 and R 10 independent of each other are a substituted or unsubstituted C 1 –C 10 alkylene divalent radical, Y 1 is a linkage of in which R 12 and R 12 ’ independent of each other are C 1 -C 6 alkyl. 29. The method of embodiment 28, wherein in formula (IIa) h1 is an integer of 3 to 20 (more preferably 3 to 15). 30. The method of embodiment 28 or 29, wherein in formula (IIa) R 12 and R 12 ’ independent of each other are methyl. 31. The method of any one of embodiments 28 to 30, wherein at least one mono- (meth)acrylamido-terminated oligo- or polysiloxane is selected from the group consisting of α-(meth)acryloyl-amidopropyloxypropyl terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-N-methyl-(meth)acryloylamidopropyloxypropyl terminated ω-C 1 - C 4 -alkyl terminated polydimethylsiloxane, α-[3-(meth)acrylamidoethoxy-2- hydroxypropyloxy-propyl]-terminated ω-C 1 -C 4 -alkyl polydimethylsiloxane, α-[3- (meth)acrylamidopropyloxy-2-hydroxypropyloxy-propyl]-termina ted ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-[3-(meth)acrylamido-isopropyloxy-2- hydroxypropyloxypropyl]-terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α- [3-(meth)acrylamidobutyloxy-2-hydroxypropyloxy-propyl]-termi nated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-[3-(meth)acryloylamido-2-hydroxypropyloxypropyl] terminated ω-C 1 -C 4 -alkyl polydimethylsiloxane, α-[3-[N-methyl-(meth)acryloylamido]-2- hydroxypropyloxypropyl] terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, N- methyl-N'-(propyl-tetra(dimethylsiloxy)dimethylbutylsilane) (meth)acrylamide, N-(2,3- dihydroxypropane)-N'-(propyltetra(dimethylsiloxy)dimethyl-bu tylsilane) (meth)acrylamide, (meth)acryloylamido-propyltetra(dimethylsiloxy)-dimethylbuty lsilane, and combinations thereof. 32. The method of any one of embodiments 13 to 31, wherein said at least one first polysiloxane vinylic crosslinker and said at least one second polysiloxane vinylic crosslinker independently of one another are selected from the group consisting of: an α,ω-(meth)acryloxy-terminated polydimethylsiloxane; an α,ω-(meth)acrylamido- terminated polydimethylsiloxane; an α,ω-vinyl carbonate-terminated polydimethylsiloxane; an α,ω-vinyl carbamate-terminated polydimethylsiloxane; a bis-3- methacryloxy-2-hydroxypropyloxypropyl polydimethylsiloxane; a reaction product of glycidyl methacrylate with a di-amino-functionalized polydimethylsiloxane; a reaction product of an azlactone-containing vinylic monomer with a di-hydroxyl-functionalized polydimethylsiloxane; and combinations thereof. 33. The method of any one of embodiments 13 to 31, wherein said at least one first polysiloxane vinylic crosslinker and said at least one second polysiloxane vinylic crosslinker independently of one another comprises at least one polysiloxane vinylic crosslinker of formula (H) in which: d1 is an integer of from 30 to 500 and d2 is an integer of from 1 to 75, provided that d2/d1 is from about 0.035 to about 0.15 (preferably from about 0.040 to about 0.12, even more preferably from about 0.045 to about 0.10); X h1 is O or NR hN in which R hN is hydrogen or C 1 -C 10 -alkyl; R h0 is hydrogen or methyl; R h1 and R h2 independently of each other are a substituted or unsubstituted C 1 –C 10 alkylene divalent radical or a divalent radical of –R h4 –O–R h5 – in which R h4 and R h5 independently of each other are a substituted or unsubstituted C 1 –C 10 alkylene divalent radical; R h3 is a monovalent radical of any one of formula (H-a) to (H-e) k1 is zero or 1; m1 is an integer of 2 to 4; m2 is an integer of 1 to 5; m3 is an integer of 3 to 6; m4 is an integer of 2 to 5; R h6 is hydrogen or methyl; R h7 is a C 2 -C 6 hydrocarbon radical having (m2+1) valencies; R h8 is a C 2 -C 6 hydrocarbon radical having (m4+1) valencies; R h9 is ethyl or hydroxymethyl; R h10 is methyl or hydromethyl; R h11 is hydroxyl or methoxy; X h1 is a sulfur linkage of –S– or a teriary amino linkage of –NR h12 – in which R h12 is C 1 -C 1 alkyl, hydroxyethyl, hydroxypropyl, or 2,3-dihydroxypropyl; and X h2 is a linkage of in which R h13 is hydrogen or C 1 -C 10 alkyl. 34. The method of any one of embodiments 13 to 31, wherein said at least one first polysiloxane vinylic crosslinker and said at least one second polysiloxane vinylic crosslinker independently of one another comprises (i) at least one polysiloxane vinylic crosslinker having one sole polydiorganosiloxane segment and two terminal ethylenically-unsaturated groups selected from the group consisting of (meth)acryloyloxy groups, (meth)acryloylamino groups, vinyl carbonate groups, vinylcarbamate groups; and/or (ii) at least one chain-extended polysiloxane vinylic crosslinker having at least two polydiorganosiloxane segment and a covalent linker between each pair of polydiorganosiloxane segments and two two terminal ethylenically-unsaturated groups selected from the group consisting of (meth)acryloyloxy groups, (meth)acryloylamino groups, vinyl carbonate groups, vinylcarbamate groups. 35. The method of any one of embodiments 13 to 31, wherein said at least one first polysiloxane vinylic crosslinker and said at least one second polysiloxane vinylic crosslinker independently of one another comprises (i) at least one polysiloxane vinylic crosslinker selected from the group consisting of α,ω-bis[3-(meth)acrylamidopropyl]- terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxy-2-hydroxypropyloxypropyl]-termina ted polydimethylsiloxane, α,ω-bis[3-(meth)acryloxyethoxy-2-hydroxypropyloxypropyl]- terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxy-propyloxy-2- hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxy- isopropyloxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3- (meth)acryloxybutyloxy-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamidoethoxy-2-hydroxypropyloxypropyl] -terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamidopropyloxy-2-hydroxypropyloxyprop yl]- terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamido-isopropyloxy-2- hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3- (meth)acrylamidobutyloxy-2-hydroxypropyloxypropyl]-terminate d polydimethylsiloxane, α,ω-bis[3-(meth)acryloxyethylamino-2-hydroxypropyloxypropy l]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxypropylamino-2-hydroxypropyloxyprop yl]- terminated polydimethylsiloxane, α,ω-bis[3-(meth)acryloxybutylamino-2- hydroxypropyloxy-propyl]-terminated polydimethylsiloxane, α,ω- bis[(meth)acrylamidoethylamino-2-hydroxypropyloxy-propyl]-te rminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamido-propylamino-2- hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω-bis[3-(meth)acrylamide- butylamino-2-hydroxypropyloxypropyl]-terminated polydimethylsiloxane, α,ω- bis[(meth)acryloxy-2-hydroxypropyloxy-ethoxypropyl]-terminat ed polydimethylsiloxane, α,ω-bis[(meth)acryloxy-2-hydroxypropyl-N-ethylaminopropyl] -terminated polydimethylsiloxane, α,ω-bis[(meth)acryloxy-2-hydroxypropyl-aminopropyl]- polydimethylsiloxane, α,ω-bis[(meth)acryloxy-2-hydroxypropyloxy- (polyethylenoxy)propyl]-terminated polydimethylsiloxane, α,ω- bis[(meth)acryloxyethylamino-carbonyloxyethoxy-propyl]-termi nated polydimethylsiloxane, α,ω-bis[(meth)acryloxyethylamino-carbonyloxy- (polyethylenoxy)propyl]-terminated polydimethylsiloxane, and combinations thereof. 36. The method of any one of embodiments 13 to 31, wherein said at least one first polysiloxane vinylic crosslinker and said at least one second polysiloxane vinylic crosslinker independently of one another comprises at least one polysiloxane vinylic crosslinker having a polymer chain segment (i.e., a divalent radical) of which SN is an integer of 3 or larger and each of R S1 and R S2 independent of one another are selected from the group consisting of: C 1 -C 10 alkyl; phenyl; C 1 -C 4 -alkyl- substituted phenyl; C 1 -C 4 -alkoxy-substituted phenyl; phenyl-C 1 -C 6 -alkyl; C 1 -C 10 fluoroalkyl; C 1 -C 10 fluoroether; aryl; aryl C 1 -C 18 alkyl; –alk–(OC 2 H 4 ) ^1 –OR o (in which alk is C 1 -C 6 alkylene diradical, R o is H or C 1 -C 4 alkyl and ^1 is an integer from 1 to 10); a C 2 –C 40 organic radical having at least one functional group selected from the group consisting of hydroxyl group (-OH ), carboxyl group (-COOH), amino linkages of –NR N1 – , amide linkages of –CONR N1 –, amide of –CONR N1 R N1 ’, urethane linkages of –OCONH– , and C 1 -C 4 alkoxy group, or a linear hydrophilic polymer chain, in which R N1 and R N1 ’ independent of each other are hydrogen or a C 1 -C 15 alkyl. 37. The method of any one of embodiments 13 to 31, wherein said at least one first polysiloxane vinylic crosslinker and said at least one second polysiloxane vinylic crosslinker independently of one another comprises at least one polysiloxane vinylic crosslinker of formula (1) or (2) i n which: R o is H or methyl; ν1 is an integer of from 30 to 500; ν2 and ν3 independent of each other are an integer of from 5 to 100; ω2 and ω3 independent of each other are an integer of from 1 to 15; a1 and g1 independent of each other is zero or 1; L 1 ’ is a C 2 -C 8 alkylene divalent radical which has zero or one hydroxyl group; L 1 ” is C 3 -C 8 alkylene divalent radical which has zero or one hydroxyl group; L 2 is a divalent radical of , ; L 3 is a divalent radical of in which PE is a divalent radical of L 3 ’ is C 3 -C 8 alkylene divalent radical; R 2 is a C 4 -C 14 hydrocarbon divalent radical; R 3 is a C 2 -C 6 alkylene divalent radical; X o , X 1 ’, and X o1 independent of one another are O or NR 1 ; X 1 is O, NR 1 , NHCOO, OCONH, CONR 1 , or NR 1 CO; Z 0 is a direct bond or a C 1 -C 12 alkylene divalent radical. 38. The method of any one of embodiments 13 to 37, wherein said at least one silicone- containing vinylic monomer comprises at least one silicone-containing vinylic monomer of formula (M1) or (M2): in which: a M1 is zero or 1; R M0 is H or methyl; X M0 is O or NR M1 ; L M1 is a C 2 -C 8 alkylene divalent radical or a divalent radical of a C 2 -C 8 alkylene divalent radical which has zero or one hydroxyl group; L M1 ” is C 3 -C 8 alkylene divalent radical which has zero or one hydroxyl group; X M1 is O, NR M1 , NHCOO, OCONH, CONR M1 , or NR M1 CO; R M1 is H or a C 1 -C 4 alkyl having 0 to 2 hydroxyl group; R t1 and R t2 independent of each other are a C 1 -C 6 alkyl; X M1 ’ is O or NR 1 ; v1 is an integer of 1 to 30; v2 is an integer of 0 to 30; n1 is an integer of 3 to 40; and r1 is an integer of 2 or 3. 39. The method of embodiment 38, wherein said at least one silicone-containing vinylic monomer comprises tris(trimethylsilyloxy)silylpropyl (meth)acrylate, [3-(meth)acryloxy-2- hydroxypropyloxy]propylbis(trimethylsiloxy)methylsilane, [3-(meth)acryloxy-2- hydroxypropyloxy]propylbis(trimethylsiloxy)butylsilane, 3-(meth)acryloxy-2-(2- hydroxyethoxy)propyloxy)propylbis(trimethylsiloxy)methylsila ne, 3-(meth)acryloxy-2- hydroxypropyloxy)propyltris(trimethylsiloxy)silane, N-2-(meth)acryloxyethyl-O-(methyl- bis-trimethylsiloxy-3-propyl)silyl carbamate, 3-(trimethylsilyl)propylvinyl carbonate, 3- (vinyloxycarbonylthio)propyltris(trimethylsiloxy)silane, 3-[tris(trimethylsiloxy)silyl]- propylvinyl carbamate, 3-[tris(trimethylsiloxy)silyl] propyl allyl carbamate, 3- [tris(trimethylsiloxy)silyl]-propyl vinyl carbonate, or a combination thereof. 40. The method of any one of embodiments 13 to 37, wherein said at least one silicone- containing vinylic monomer comprises at least one silicone-containing vinylic monomer selected from the group consisting of α-(meth)acryloxypropyl terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-(meth)acryloxy-2-hydroxypropyloxypropyl terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-(2-hydroxyl- methacryloxypropyloxypropyl)-ω-C 1 -C 4 -alkyl-decamethylpentasiloxane, α-[3- (meth)acryloxyethoxy-2-hydroxypropyloxypropyl]-terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-[3-(meth)acryloxy-propyloxy-2-hydroxypropyloxypropyl]- terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-[3- (meth)acryloxyisopropyloxy-2-hydroxypropyloxypropyl]-termina ted ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-[3-(meth)acryloxybutyloxy-2- hydroxypropyloxypropyl]-terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α- [3-(meth)acryloxyethylamino-2-hydroxypropyloxypropyl]-termin ated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-[3-(meth)acryloxypropylamino-2- hydroxypropyloxypropyl]-terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α- [3-(meth)acryloxy-butylamino-2-hydroxypropyloxypropyl]-termi nated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-(meth)acryloxy-(polyethylenoxy)-2- hydroxypropyloxypropyl]-terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α- [(meth)acryloxy-2-hydroxypropyloxy-ethoxypropyl]-terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-[(meth)acryloxy-2-hydroxypropyl-N-ethylaminopropyl]- terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-[(meth)acryloxy-2- hydroxypropyl-aminopropyl]-terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-[(meth)acryloxy-2-hydroxypropyloxy-(polyethylenoxy)propyl ]-terminated ω-C 1 -C 4 -alkyl terminated polydimethylsiloxane, α-vinyl carbonate-terminated ω-C 1 -C 4 -alkyl-terminated polydimethylsiloxanes, α-vinyl carbamate-terminated ω-C 1 -C 4 -alkyl-terminated polydimethylsiloxane, or a mixture thereof. 41. The method of any one of embodiments 13 to 40, wherein the sum of the amounts of components (a), (b) and (c) in the monomer mixture is at least about 60% by weight relative to the total weight of all polymerizable materials present in the monomer mixture. 42. The method of any one of embodiments 13 to 40, wherein the sum of the amounts of components (a), (b) and (c) in the monomer mixture is at least about 65% by weight relative to the total weight of all polymerizable materials present in the monomer mixture. 43. The method of any one of embodiments 13 to 40, wherein the sum of the amounts of components (a), (b) and (c) in the monomer mixture is at least about 70% by weight relative to the total weight of all polymerizable materials present in the monomer mixture. 44. The method of any one of embodiments 13 to 40, wherein the sum of the amounts of components (a), (b) and (c) in the monomer mixture is at least about 75% by weight relative to the total weight of all polymerizable materials present in the monomer mixture. 45. The method of any one of embodiments 1 to 44, wherein said at least one first and second polymerizable materials independent of each other comprises at least one non- silicone vinylic crosslinker. 46. The method of any one of embodiments 1 to 44, wherein said at least one first and second polymerizable materials independent of each other comprises at least one non- silicone vinylic crosslinker selected from the group consisting of ethyleneglycol di- (meth)acrylate, diethyleneglycol di-(meth)acrylate, triethyleneglycol di-(meth)acrylate, tetraethyleneglycol di-(meth)acrylate, glycerol di-(meth)acrylate, 1,3-propanediol di- (meth)acrylate, 1,3-butanediol di-(meth)acrylate, 1,4-butanediol di-(meth)acrylate, glycerol 1,3-diglycerolate di-(meth)acrylate, ethylenebis[oxy(2-hydroxypropane-1,3-diyl)] di-(meth)acrylate, bis[2-(meth)acryloxyethyl] phosphate, trimethylolpropane di- (meth)acrylate, and 3,4-bis[(meth)acryloyl]tetrahydrofuan, diacrylamide (i.e., N-(1-oxo-2- propenyl)-2-propenamide), dimethacrylamide (i.e., N-(1-oxo-2-methyl-2-propenyl)-2- methyl-2-propenamide), N,N-di(meth)acryloyl-N-methylamine, N,N-di(meth)acryloyl-N- ethylamine, N,N’-methylene bis(meth)acrylamide, N,N’-ethylene bis(meth)acrylamide, N,N’-dihydroxyethylene bis(meth)acrylamide, N,N’-propylene bis(meth)acrylamide, N,N’- 2-hydroxypropylene bis(meth)acrylamide, N,N’-2,3-dihydroxybutylene bis(meth)acrylamide, 1,3-bis(meth)acrylamide-propane-2-yl dihydrogen phosphate (i.e., N,N’-2-phophonyloxypropylene bis(meth)acrylamide), piperazine diacrylamide (or 1,4- bis(meth)acryloyl piperazine), tetraethyleneglycol divinyl ether, triethyleneglycol divinyl ether, diethyleneglycol divinyl ether, ethyleneglycol divinyl ether, triallyl isocyanurate, triallyl cyanurate, trimethylopropane trimethacrylate, pentaerythritol tetramethacrylate, bisphenol A dimethacrylate, and combinations thereof. 47. The method of any one of embodiments 1 to 44, wherein said at least one first and second polymerizable materials independent of each other comprises at least one non- silicone vinylic crosslinker selected from the group consisting of tetra(ethyleneglycol) di- (meth)acrylate, tri(ethyleneglycol) di-(meth)acrylate, ethyleneglycol di-(meth)acrylate, di(ethyleneglycol) di-(meth)acrylate, tetraethyleneglycol divinyl ether, triethyleneglycol divinyl ether, diethyleneglycol divinyl ether, ethyleneglycol divinyl ether, triallyl isocyanurate, triallyl cyanurate, or a combination thereof. 48. The method of any one of embodiments 1 to 47, wherein said at least one first and second polymerizable materials independent of each other comprises at least one non- silicone hydrophobic vinylic monomer. 49. The method of any one of embodiments 1 to 47, wherein said at least one first and second polymerizable materials independent of each other comprises at least one C 1 -C 8 alkyl (meth)acrylate, at least one C 5 -C 16 cycloalkyl (meth)acrylate, at least one aryl methacrylate, (meth)acrylonitrile, at least one fluorine-containing acrylic monomer, at least one vinyl alkanoate, at least one vinyloxyalkane, at least one substituted or unsubstituted styrene, vinyl toluene, vinyl chloride, vinylidene chloride, 1-butene, or combinations thereof. 50. The method of embodiment 49, wherein said at least one vinyl alkanoate is selected from the group consisting of vinyl acetate, vinyl propionate, vinyl butyrate, vinyl valerate, and combinations thereof, wherein said at least one vinyloxyalkane is selected from the group consisting of vinyl ethyl ether, propyl vinyl ether, n-butyl vinyl ether, isoputyl vinyl ether, cyclohexyl vinyl ether, t-butyl vinyl ether, and combinations thereof, wherein said at least one fluorine-containing acrylic monomer is selected from the group consisting of 2,2,2-trifluoroethyl (meth)acrylate, tetrafluoropropyl (meth)acrylate, hexafluoro-iso- propyl (meth)acrylate, hexafluorobutyl (meth)acrylate, heptafluorobutyl (meth)acrylate, octafluoropentyl (meth)acrylate, heptadecafluorodecyl (meth)acrylate, pentafluorophenyl (meth)acrylate, perfluorohexylethyl-thio-carbonyl-aminoethyl-methacrylate, and combinations thereof. 51. The method of any one of embodiments 1 to 47, wherein said at least one first and second polymerizable materials independent of each other comprises methyl methacrylate, ethyl methacrylate, isopropyl methacrylate, sec-butyl methacrylate, tert- butyl methacrylate, cyclohexyl methacrylate, isobornyl acrylate, isobornyl methacrylate, phenyl methacrylate, 4-tert-butylstyrene, 2-methylstyrene, styrene, 4-ethoxystyrene, 2,4-dimethystyrene, 2,5-dimethylstyrene, 3,5-dimethylstyrene, or combinations thereof. 52. The method of any one of embodiments 1 to 47, wherein said at least one first and second polymerizable materials independent of each other comprises methyl methacrylate, tert-butyl methacrylate, cyclohexyl methacrylate, isobornyl acrylate, isobornyl methacrylate, or combinations thereof. 53. The method of any one of embodiments 1 to 47, wherein said at least one first and second polymerizable materials independent of each other comprises methyl methacrylate, tert-butyl methacrylate, cyclohexyl methacrylate, or combinations thereof. 54. The method of any one of embodiments 1 to 53, wherein said at least one first and second polymerizable materials independent of each other comprises at least one UV- absorbing vinylic monomer. 55. The method of any one of embodiments 1 to 53, wherein said at least one first and second polymerizable materials independent of each other comprises 2-[2'-hydroxy-5'- (2-methacryloxyethyl)phenyl)]-2H-benzotriazole (Norbloc). 56. The method of any one of embodiments 1 to 55, wherein said at least one photochromic compound comprises a naphthopyran, an indeno-fused naphthopyran (i.e., indeno- naphthopyran), a heterocyclic ring-fused naphthopyrian, a benzopyran, a phenanthropyran, a quinopyran, a quinolinopyran, a fluoroanthenopyran, an anthracene-fused pyran, a tetracene-fused pyran, a spiro(benzindoline) naphthopyran, a spiro(indoline)naphthopyran, a spiro(indoline)benzopyran, a spiro(indoline)quinopyran, a spiro(indoline)pyran, a naphthoxazine, a spirobenzopyran, a spirobenzothiopyran, a naphthacenedione, a benzoxazine, a spirooxazine, a naphthoxazine, a spiro(benzindoline)naphthoxazine, a spiro(indoline)naphthoxazine, a spiro(indoline)pyrido-benzoxazine, a spiro(indoline)benzoxazine, a spiro(benzindoline) benzoxazine, a spiro(benzindoline)pyridobenzoxazine, a spiro(indoline) fluoranthenoxazine, a spiro(indoline)-quinoxazine, a spiropiperidine-naphthopyran, a piro(indoline)pyronobenzoxazinone, a benzospiropyran, a naphthospiropyran, a spirobenzoxazine-pyrrolopyridine, a spironaphthoxazine-pyrrolopyrridine, a spiro- oxazepin-benzoxazine, a spiro-oxazepin-naphthoxazine, a spiro(indoline) benzothiazoloxazine, a spiro(indoline)benzopyrroloxazine, a spiro(indoline)quinazolino- oxazine, a spiro(indoline)-anthracenobenzoxazine, a benzofurobenzopyran, a benzothienobenzopyran, a naphthofurobenzopyran, a benzopyrano-fused naphthopyran, a spiro(isoindoline)-naphthoxazine, a spiro(isoindoline)benzoxazine, or a mixture thereof. 57. The method of any one of embodiments 1 to 56, wherein said at least one photochromic compound is polymerizable (i.e., comprising an ethylenicaly-unsaturated group). 58. The method of embodiment 57, wherein said at least one photochromic compound is a coupling reaction product of a reactive (meth)acrylamido or (meth)acryloxy monomer having a first reactive functional group and a reactive photochromic compound have a second reactive functional group in the absence or presence of a coupling agent under coupling reaction, wherein the first reactive functional group is selected from the group consisting ; wherein the second reactive functional group is selected from the group consisting wherein R 0 is hydrogen or methyl and R N2 is hydrogen, a linear or branched C 1 -C 15 alkyl, cyclohexyl, cyclopentyl, a substituted or unsubstituted phenyl, or a substituted- or unsubstituted-phenyl-C 1 -C 6 alkyl. 59. The method of embodiment 58, wherein the reactive (meth)acrylamido or (meth)acryloxy monomer is selected from the group consisting of (meth)acryloyl halides (CH 2 =CH─COX or CH 2 =CCH 3 ─COX, X= Cl or Br), N-hydroxysuccinimide ester of (meth)acrylic acid, glycidyl (meth)acrylate, isocyanato- C 2 -C 6 alkyl (meth)acrylate, amino–C 2 -C 6 alkyl (meth)acrylamide, C 1 -C 6 alkylamino–C 2 -C 6 alkyl (meth)acrylamide, (meth)acrylic acid, C 2 -C 4 alkylacrylic acid (e.g., ethylacrylic acid, propylacrylic acid, butylacrylic acid), N-2-acrylamidoglycolic acid, 3-(acryloylxy)propanoic acid, C 2 -C 6 hydroxylalkyl (meth)acrylate, C 2 -C 6 hydroxyalkyl (meth)acrylamide, azlactone-containing vinylic monomers (e.g., 2-vinyl-4,4-dimethyl-1,3-oxazolin-5-one, 2-isopropenyl-4,4- dimethyl-1,3-oxazolin-5-one, 2-vinyl-4-methyl-4-ethyl-1,3-oxazolin-5-one, 2-isopropenyl- 4-methyl-4-butyl-1,3-oxazolin-5-one, 2-vinyl-4,4-dibutyl-1,3-oxazolin-5-one, 2- isopropenyl-4-methyl-4-dodecyl-1,3-oxazolin-5-one, 2-isopropenyl-4,4-diphenyl-1,3- oxazolin-5-one, 2-isopropenyl-4,4-pentamethylene-1,3-oxazolin-5-one, 2-isopropenyl- 4,4-tetramethylene-1,3-oxazolin-5-one, 2-vinyl-4,4-diethyl-1,3-oxazolin-5-one, 2-vinyl-4- methyl-4-nonyl-1,3-oxazolin-5-one, 2-isopropenyl-4-methyl-4-phenyl-1,3-oxazolin-5-one, 2-isopropenyl-4-methyl-4-benzyl-1,3-oxazolin-5-one, 2-vinyl-4,4-pentamethylene-1,3- oxazolin-5-one, and 2-vinyl-4,4-dimethyl-1,3-oxazolin-6-one, with 2-vinyl-4,4-dimethyl- 1,3-oxazolin-5-one (VDMO) and 2-isopropenyl-4,4-dimethyl-1,3-oxazolin-5-one (IPDMO) as preferred azlactone-containing vinylic monomers), aziridinyl C 1 -C 12 alkyl (meth)acrylate (e.g., 2-(1-aziridinyl) ethyl (meth)acrylate, 3-(1-aziridinyl) propyl (meth)acrylate, 4-(1-aziridinyl) butyl (meth)acrylate, 6-(1-aziridinyl) hexyl (meth)acrylate, or 8-(1-aziridinyl) octyl (meth)acrylate), acrolein, methacrolein, crotonaldehyde, and combinations thereof. 60. The method of embodiment 58 or 59, wherein the reactive photochromic compound comprises 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxyethoxy-13-p henyl- 3H,13H-indeno [2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl- 13-(2-hydroxycarbonylethyl)carboxyethoxy-13-phenyl-3H,13H-in deno [2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13- phenyl-3H,13H-indeno [2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11- dimethyl-13-(2-hydroxycarbonylethyl)carboxy-13-phenyl-3H,13H -indeno [2’,3’:3,4] naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-propyl- 3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl- 13-(2-hydroxycarbonylethyl)carboxy-13-propyl-3H,13H-indeno[2 ’,3’:3,4]-naphtho[1,2- b]pyran; 3,3-di(4-methoxyphenyl)-10,11-dimethoxy-13-hydroxy-13-ethyl- 3H,13H- indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-10,11-dimethoxy-13-(2- hydroxycarbonylethyl)carboxy-13-ethyl-3H,13H-indeno[2,1-f]na phtho[1,2-b]pyran; 3,3- bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-hydroxymethyl-13 -methyl-3H,13H- indeno[2’,3’:3,4] naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-7-methoxy-11-phenyl- 13-(2-hydroxycarbonylethyl)carboxymethyl-13-methyl-3H,13H-in deno[2’,3’:3,4]- naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-7-methoxy-11-phenyl-13-hydroxy-13- methyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-7- methoxy-11-phenyl-13-(2-hydroxycarbonylethyl)carboxy-13-meth yl-3H,13H-indeno- [2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-11-phenyl-13-hydroxy-13- methyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-11- phenyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H,13H-i ndeno[2’,3’:3,4]- naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7,10,11-tetramethoxy-13-hydroxy-13 - ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,7,10,11- tetramethyl-13-(2-hydroxycarbonylethyl)carboxy-13-methyl-3H, 13H-indeno[2’,3’:3,4]- naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7-dimethoxy-13-hydroxy-13-ethyl- 3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-11-(4-(4,5- diphenyl-1H-imidazol-2-yl)phenyl-13,13-dimethyl-3H,13H-inden o[2’,3’:3,4]naphtho[1,2- b]pyran; 3,3-di(4-methoxyphenyl)-6-methoxy-7-(3-hydroxymethylenepiper idin-1-yl)- 13,13-dimethyl-3H,13H-indeno[2’,3':3,4]naphtho[1.2-b]pyran ; 3,3-di(4-methoxyphenyl)- 6-methoxy-7-(3-(2-hydroxycarbonylethyl)-carboxymethylenepipe ridin-1-yl)-13,13- dimethyl-3H,13H-indeno[2’,3':3,4]naphtho[1.2-b]pyran; 3,3-di(4-methoxyphenyl)-6,7- dimethoxy-13-hydroxy-13-butyl-3H,13H-indeno[2,1-f]naphtho[1, 2-b]pyran; 3,3-di(4- methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-hydroxyethoxy)-eth oxy)-indeno[2,1- f]naptho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,11,13-trimethyl-13-(2-(2-(2-(2- hydroxyethoxy)ethoxy)ethoxy)ethoxy)-indeno[2,1-f]naptho[1,2- b]pyran; 3,3-diphenyl-13- hydroxy-13-(2-oxo-2-ethoxyethyl)-1H-indeno[2,1-f]naphtho[1,2 -b]pyran; 3,3-di(4- methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-(2-oxo-2-ethoxyet hyl)-1H-indeno[2,1- f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-6,11-dimethyl-13-butyl-13-hydroxy- indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-bis(4-hydroxyphenyl)-7-methoxy-11-phenyl-13,13- diethyl-3H,13H-indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-hydroxyphenyl)-7- methoxy-11-phenyl-13,13-dipropyl-3H,13H-indeno[2’,3’:3,4 ]naphtho[1,2-b]pyran; 3,3- bis(4-hydroxyphenyl)-7-methoxy-11-phenyl-13-carbomethoxy-13- methyl-3H,13H- indeno[2’,3’:3,4] naphtho[1,2-b]pyran; 3,3-diphenyl-6,7-dimethoxy-13-methyl-13-methyl- 13-hydroxyethoxy-ethoxyethoxy-3H,13H-indeno[2’,3’:3,4]na phtho[1,2-b]pyran; 3,3- diphenyl-6,7,10,11-tetramethoxy-13-ethyl-13-methyl-13-hydrox yethoxyethoxy-3H,13H- indeno[2’,3’:3,4]naphtho [1,2-b]pyran; 6,7-dimthoxy-2,2-diphenyl-13-hydroxy-13-butyl- 2H,13H-indeno[1’,2’:4,3] naphtho[1,2-b]pyran; 6,7-dimthoxy-2,2-diphenyl-13-hydroxy- 13-methyl-2H,13H-indeno[1’,2’:4,3]naphtho[1,2-b]pyran; 6,7-dimthoxy-2,2-diphenyl-13- hydroxy-2H,13H-indeno[1’,2’:4,3]naphtho[1,2-b]pyran; 3-(4-allyloxyphenyl)-3-(4- morpholinophenyl)-7-methoxy-11-phenyl-13,13-dimethy-3H,13H- indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10- (piperazin-1-yl)-6-trifluoromethyl-13,13-dimethyl-3H,13H-ind eno[2’,3’:3:4]naphtho[1,2- b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10-(4-hydroxybenzamido )-6- trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2’,3’:3:4]n aphtho[1,2-b]pyran; 3-(4- fluorophenyl)-3-(4-butoxyphenyl)-10-vinyl-6-trifluoromethyl- 13,13-dimethyl-3H,13H- indeno[2’,3’:3:4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4-butoxyphenyl)-10- (carboxylic acid)-6-trifluoromethyl-13,13-dimethyl-3H,13H-indeno[2’,3 :3:4]naphtho[1,2- b]pyran; 3-(4-fluorophenyl)-3-(4-methoxyphenyl)-6-methoxy-7-(4-hydrox ypiperidin-1-yl)- 13,13-dimethyl-3H,13H-indeno[2',3’:3,4]naphtho[1,2-b]pyran ; 3-(4-fluorophenyl)-3-(4- methoxyphenyl)-6-methoxy-7-(4-(2-hydroxycarbonylethyl) carboxypiperidin-1-yl)-13,13- dimethyl-3H,13H-indeno[2',3’:3,4]naphtho[1,2-b]pyran; 3-(4-fluorophenyl)-3-(4- morpholinophenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-13,1 3-dimethyl-3H,13H- indeno[2',3’:3,4]naphtho[1.2-b]pyran; 3-(4-fluorophenyl)-3-(4-morpholinophenyl)-6- methoxy-7-(4-(2-hydroxycarbonylethyl) carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H- indeno[2',3’:3,4] naphtho[1.2-b]pyran; 3-(4-hydroxyethoxyphenyl)-3-(4-methoxyphenyl)- 11-(4-(N,N-dimethylamino)phenyl)-13,13-dimethyl-3H,13H-inden o[2’,3’:3,4]naphtho[1,2- b]pyran; 3-(4-methoxyphenyl)-3-(2,4-dimethoxyphenyl)-phenyl-6,11-dime thoxy-13- methyl-13-methyl-13-hydroxyethoxyethoxyethoxy-3H,13H-indeno[ 2’,3’:3,4]naphtho[1,2- b]pyran; 3-(4-methoxyphenyl)-3-(3-methyl-4-methoxyphenyl)-13-hydroxy- indeno[2,1- f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-6,7,10,11- tetramethoxy-13-hydroxy-13-ethyl-3H,13H-indeno[2,1-f]naphtho [1,2-b]pyran; 3-(4- methoxyphenyl)-3-(4-morpholinophenyl)-6,7,10,11-tetramethoxy -13-hydroxy-13-butyl- 3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)- 6,7-dimethoxy-13-hydroxy-13-ethyl-3H,13H-indeno [2,1-f]naphtho[1,2-b]pyran; 3-(4- methoxyphenyl)-3-(4-morpholinophenyl)-6,7-dimethoxy-13-hydro xy-13-methyl-3H,13H- indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-(4-morpholinophenyl)-13-oxo- 3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-phenyl-6-methoxy-7- mprphlino-13-methyl-13-methyl-13-hydroxyethoxyethoxyethoxy-3 H,13H- indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-(4-methoxyphenyl)-3-phenyl-6,11-dimethoxy-13- methyl-13-methyl-13-hydroxyethoxy-ethoxy-3H,13H-indeno[2’, 3’:3,4]naphtho[1,2- b]pyran; 2-(4-methoxyphenyl)-2-(4-morpholinophenyl)-5-hydroxy-6-carbo ethoxy-2H- naphtho[1,2-b] pyran; 3-(4-morpholinophenyl)-3-phenyl-6,7-dimethoxy-13-hydroxy-13- ethyl-3H,13H-indeno[2,1-f]naphtho[1,2-b]pyran; 3-(4-morpholinophenyl)-3-phenyl-6,7- dimethoxy-13-hydroxy-13-butyl-3H,13H-indeno[2,1-f]naphtho[1, 2-b]pyran; 3-(4- morpholinophenyl)-3-phenyl-6,7-dimethoxy-13-oxo-3H,13H-inden o[2,1-f]naphtho[1,2- b]pyran; 3-phenyl-3-(4-hydroxyethoxyphenyl)-6-methoxy-7-morpholino-13 ,13-dimethyl- 3H,13H-indeno-[2',3’:3,4] naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2- hydroxycarbonylethyl)carboxyethoxy-phenyl)-6-methoxy-7-morph olino-13,13-dimethyl- 3H,13H-indeno[2',3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxyethoxy)phenyl)- 6-methoxy-7-piperidino-13,13-dimethy-3H,13H-indene[2’,3’ :3,4]naphtho[1,2-b]pyran; 3- phenyl-3-(4-(2-(2-hydroxycarbonylethyl)-carboxyethoxy)phenyl )-6-methoxy-7-piperidino- 13,13-dimethy-3H,13H-indene[2’,3’:3,4] naphtho[1,2-b]pyran; 3-phenyl-3-(4- hydroxyphenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2 ,3’:3,4]naphtho[I,2- b]pyran; 3-phenyl-3-(4-hydroxyethoxy)phenyl)-6,7-dimethoxy-13,13-dime thyl-3H,13H- indeno[2’,3’:3,4]-naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2- hydroxycarbonylethyl)carboxyethoxy)phenyl)-6,7-dimethoxy-13, 13-dimethyl-3H,13H- indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(2-hydroxycarbonylethyl)carboxy- phenyl)-6,7-dimethoxy-13,13-dimethyl-3H,13H-indeno[2’,3’ :3,4]naphtho[I,2-b]pyran; 3- phenyl-3-(4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)-13,13- dimethyl-3H,13H- indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-(2-(2-hydroxycarbonylethyl)- carboxyethyl)piperazin-1-yl)phenyl)-13,13-dimethyl-3H,13H-in deno[2’,3’:3,4]naphtho- [1,2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-piperazinyl-13,13-d imethyl- 3H,13H-indene[2’,3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy- 7-(3-hydroxymethylenepiperidin-1-yl)-13,13-dimethyl-3H,13H-i ndeno [2’,3”:3.4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(3-(2- hydroxycarbonylethyl) carboxymethylenepiperidin-1-yl)-13,13-dimethyl-3H,13H- indeno[2’,3”:3.4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(4- hydroxypipendin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4 ]naphtho-[1,2-b]pyran; 3- phenyl-3-(4-methoxyphenyl)-6-methoxy-7-(4-(2-hydroxycarbonyl ethyl)-carboxypipendin- 1-yl)-13,13-dimethyl-3H,13H-indeno[2',3':3,4]naphtho[1,2-b]p yran; 3-phenyl-3-(4-(4- methoxyphenyl-piperazin-1-yl)phenyl)-13,13-dimethyl-6-methox y-7-hydroxy-indeno [2’,3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-methoxyphenyl-piperazin-1-yl)phenyl)- 13,13-dimethyl-6-methoxy-7-(2-hydroxy-2-methyl-3-butyn-4-yl) -indeno[2’,3’:3,4]naphtho [1,2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(3-hydroxymethyl ene- piperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2',3’:3,4]nap htho-[1,2-b]pyran; 3-phenyl-3- (4-morpholinophenyl)-6-methoxy-7-(3-(2-hydroxycarbonyl-ethyl )carboxymethylene- piperidin-1-yl)-13,13-dimethyl-3H,13H-indeno [2’,3’:3.4]-naphtho[1,2-b]pyran; 3-phenyl- 3-(4-morpholinophenyl)-6-methoxy-7-(3-(2-hydroxycarbonylethy l)carboxymethylene- piperidin-1-yl)-13,13-dimethyl-3H,13H-indeno [2',3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3- (4-morpholinophenyl)-6-methoxy-7-(4-hydroxypiperidin-1-yl)-1 3,13-dimethyl-3H,13H- indeno[2’,3’:3,4]naphtho[1.2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-(4- (2-hydroxycarbonylethyl)-carboxypiperidin-1-yl)-13,13-dimeth yl-3H,13H-indeno[2’,3’:3,4] naphtho[1.2-b]pyran; 3-phenyl-3-(4-morpholinophenyl)-6-methoxy-7-piperazinyl-13,1 3- dimethyl-3H,13H-indeno[2’,3’:3,4]naphtho [1.2-b]pyran; 3-phenyl-3-(4- morpholinophenyl)-6,11-dimethyl-13-hydroxy-13-(1-oxo-methoxy prop-2-yl)-1H- indeno[2,1-f]naphtho[1,2-b]pyran; 3-phenyl-3-(4-(4-phenylpiperazino)-phenyl)-6- methoxy-7-(4-hydroxypiperidin-1-yl)-13,13-dimethyl-3H,13H-in deno[2’,3':3,4] naphtho[1.2-b]pyran; 3-phenyl-3-(4-(4-phenylpiperazino)phenyl)-6-methoxy-7-(4-(2- hydroxycarbonylethyl) carboxypiperidin-1-yl)-13,13-dimethyl-3H,13H-indeno[2’,3': 3,4] naphtho[1.2-b]pyran; 3-phenyl-3-(4-piperazinylphenyl)-6,11-dimethoxy-13,13-dimeth yl- 3H,13H-indeno[2’,3’:3,4]naphtho-[1,2-b]pyran; 3-phenyl-3-(4-piperazinylphenyl)-6- methoxy-7-piperidinyl-13,13-dimethyl-3H,13H-indeno[2’,3’ :3,4]naphtho[1,2-b]pyran; 3- phenyl-3-(4-(3-methylpiperazin-1-yl)phenyl)-6-methoxy-7-(dec ahydroisoquinolin-2-yl)- 11-tert-butyl-13,13-dimethyl-3H,13H-indeno[2’,3’:3,4]nap htho[1,2-b]pyran; 3-(4- methoxyphenyl)-3-(4-morpholinophenyl)-16-(ethoxycarnobyl)met hyl-16-hydroxy-3,16- dihydrobenzofuro-[2’,3’:7,8] indeno[2’,3’:3,4]naphtho[1,2-b]pyran; 3-phenyl-3-(4- methoxyphenyl)-16-(ethoxycarnobyl)-methyl-16-hydroxy-3,16-di hydrobenzofuro [2”,3”:6’,7’]indeno-[3’,2’:4,3]naphtho[1,2-b]pyr an; 3-phenyl-3-(4-morpholinophenyl)-16- (ethoxycarnobyl)-methyl-16-hydroxy-3,16-dihydrobenzofuro[2 ,3”:6’,7’]indeno[3’,2’:4,3] naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-(ethoxycarbonyl)methyl-16-hydroxy - 3,16-dihydro-benzofuro[2’,3’:7,8]indeno[2’,3’:3,4] naphtho[1,2-b]pyran; 3,3-di(4- methoxyphenyl)-16-hydroxy-16-ethyl-16H-benzofuro[2’,3’:7 ,8] indeno[2’,3’:3,4]naphtho [1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-hydroxy-16H-benzofuro [2”,3”:6,7]indeno [3’,2’:4,3]naphtho-[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-16-hydroxy-16-ethyl-16H- benzofuro[2”,3”:6,7]-indeno[3’,2’:4,3]naphtho[1,2-b] pyran; 3-(4-methoxyphenyl)-3-(2,3- diydrobenzofur-5-yl)-13-hydroxy-13-methyl-indeno[2,1-f]napht ho[1,2-b]pyran; 3-(4- methoxyphenyl)-3-(2,3-dihydrobenzofur-5-yl)-6,11-difluoro-13 -hydroxy-13-(1-oxo- methoxyprop-2-yl)-1H-indeno[2,1-f]naphtho[1,2-b]pyran, or a mixture thereof. 61. The method of embodiment 58 or 59, wherein the reactive photochromic compound is 2,2-di(4-fluorophenyl)-5-hydroxycarbonyl-6-phenyl-9-methoxy- 2H-naphtho[1,2-b]pyran; 2,2-bis(4-methylphenyl)-5-methoxycarbonyl-6-hydroxy-2H-napht ho[1,2-b]pyran; 2,2- bis(4-methoxyphenyl)-5-methoxycarbonyl-6-hydroxy-[2H]-naphth o[1,2-b]pyran; 2,2- bis(4-methoxyphenyl)-5-methoxyethoxycarbonyl-6-methyl-8-viny l-2H-naphtho[1,2- b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxyethoxycarbonyl-6-methyl-8- hydroxycarbonyl-2H-naphtho [1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5- methoxycarbonyl-6-(2-hydroxyethoxy)ethoxy-[2H]-naphtho[1,2-b ]pyran; 2,2-bis(4- methoxyphenyl)-5-methoxycarbonyl-6-phenyl-9-(2-hydroxyethoxy )-[2H]-naphtho[1,2- b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxy-carbonyl-6-(4-(2-hydroxye thoxy)phenyl)- [2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-diphenylmethylol-6-hydroxy-2H- naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-diphenylmethylol-6-methoxy-2H- naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-hydroxyethoxylcarbonyl)-6-phen yl- [2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-(2-hydroxyethoxy)- ethoxycarbonyl)-6-phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-(2-(2- (2-hydroxyethoxy)ethoxy)-ethoxycarbonyl)-6-phenyl-[2H]-napht ho[1,2-b]pyran; 2,2- bis(4-methoxyphenyl)-5-(2-(2-(2-(2-hydroxyethoxy)ethoxy)etho xy)-ethoxycarbonyl)-6- phenyl-[2H]-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-methyl- 9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6- phenyl-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-hydroxymethyl-6-methoxy- 2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5-methoxycarbonyl-6-(3- aminophenyl)-2H-naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-2,5,7-trihydro-7- methylidine-5-oxo-furo-[3’,4’:3,4]naphtho[1,2-b]pyran; 2,2-bis(4-methoxyphenyl)-5- phenylthio-6-hydroxy-2H-naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-13-hydroxy-13- methyl-indeno[2,1-f]naphtho[1,2-b]pyran; 3,3-di(4-methoxyphenyl)-9-methoxycarbonyl- 8-(2-hydroxyethoxy)ethoxy-[3H]-naptho[1,2-b]pyran; 2,2-diphenyl-5-hydroxycarbonyl-9- methoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxycarbonyl-8,9-dimethoxy-2H- naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6-morpholinocarbonyl-2H-naphtho[1,2-b ]pyran; 2,2-diphenyl-5- hydroxy-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6- carbomethoxy-9-methoxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-hydroxy-6- morpholinocarbonyl-2H-naphtho[1,2-b]pyran; 2,2-diphenyl-5-methylol-6-(3- dimethylaminopropyl)methylamino-2H-naphtho[1,2-b]pyran;2,2-d iphenyl-2,5,7-trihydro- 7-methyliden-5-oxofuro-[3’,4’:3,4]naphtho[1,2-b]pyran; 2,2-spiroadamantylene-5- phenylthio-6-hydroxy-2H-naphtho[1,2-b]pyran; 2,2-diphenyl)-5-methoxycarbonyl-6- hydroxy-2H-naphtho[1,2-b]pyran; 2,2-spiro-admamtylene-5-methoxycarbonyl-6- hydroxy-2H-naphtho[1,2-b]pyran, 3,3-diphenyl-8-hydroxy-9-carbopropoxy-3H- naphtho[2,1-b]pyran; 2,2,5-triphenyl-6-carboethoxy-2H-naphtho[1,2-b]pyran; 2,2,6- triphenyl-5-(2-(2-(2-(2-hydroxyethoxy)ethoxy)-ethoxy)ethoxy) carbonyl-[2H]-naphtho[1,2- b]pyran; 2,2,6-triphenyl-5-(2-(2-(2-oxiran-2-ylmethoxy)ethoxy)ethoxy) -ethoxycarbonyl)- [2H]-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-(4-morpholinophenyl)-5-hydroxy-6- carboethoxy-2H-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-tert-butyl-5-methoxy- carbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(4-methoxyphenyl)-2-phenyl-5- methoxycarbonyl-6-hydroxy-2H-naphtho[1,2-b]pyran; 2-(4-(2-(2-hydroxyethoxy)ethoxy)- ethoxyphenyl)-2-phenyl-5-methoxycarbonyl-6-methyl-9-methoxy- [2H]-naphtho[1,2- b]pyran; 2-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)- 2-phenyl-5-methoxycarbonyl-6-(2-(2- methylprop-2-enoxyloxy)ethoxy)-[2H]-naphtho[1,2-b]pyran; 3-(4-(2-(2-hydroxyethoxy)- ethoxy)ethoxyphenyl)-3-phenyl-9-methoxycarbonyl-8-methoxy-[3 H]-naptho[1,2-b]pyran; 2-(4-morpholinophenyl)-2-phenyl-5-methoxycarbonyl-6-hydroxy- 2H-naphtho[1,2- b]pyran; 2-(9-ethylcarbazol-2-yl)-2-phenyl-5-methoxycarbonyl-6-hydrox y-2H- naphtho[1,2-b]pyran; 2-(9-phenylcarbazol-2-yl)-2-phenyl-5-methoxycarbonyl-6-hydro xy- 2H-naphtho[1,2-b]pyran; 2-(4-dimethylaminophenyl)-2-phenyl-5-methoxycarbonyl-6- hydroxy-2H-naphtho[1,2-b]pyran; 3-(2-flurophenyl)-3-(4-methoxyphenyl-8-hydroxy-9- carbopropoxy-3H-naphtho[2,1-b]pyran; 3-(2-flurophenyl)-3-(4-methoxyphenyl-8- hydroxy-9-carbomethoxy-3H-naphtho[2,1-b]pyran; 3-(2,4-dimethoxyphenyl)-3-(4- methoxyphenyl-8-hydroxy-9-carbomethoxy-3H-naphtho[2,1-b]pyra n; 3-(2,4,6- triflurophenyl)-3-(2,4,6-trimethoxy-1-naphthyl)-8-acetyl-9-c arboniloyl-3H-naphtho[2,1- b]pyran; 3-(4-methoxyphenyl)-3-(2-methyl-2,3-dihydrobenzofur-5-yl)-6- methoxy-12- hydroxymethyl-11-phenyl-3H-phenanthro[1,2-b]pyran; 5,5-bis(4-methoxyphenyl)-8- methylol-5H-fluorantheno[3,2-b]pyran; or a mixture thereof. 62. The method of embodiment 58 or 59, wherein the reactive photochromic compound is 1-hydroxyethyl-3,3-dimethylspiro[indoline-2,3’-[3H]-naphth o[2,1-b][1,4]oxazine]; 1- hydroxypropyl-3,3-dimethylspiro[indoline-2,3’-[3H]-naphtho [2,1-b][1,4]oxazine]; 1- aminoethyl-3,3-dimethyl-5-chlorospiro[indoline-2,3’-[3H]-n aphtho[2,1-b][1,4]oxazine]; 1- hydroxyethyl-3,3-dimethyl-8’-methoxyspiro[indoline-2,3’- [3H]-naphtho[2,1- b][1,4]oxazine]; 1-(p-vinylphenyl)-3,3-dimethyl-5,6-dichlorospiro[indoline-2, 3’-[3H]- naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-9’-hydroxyspiro[indoline-2,3’-[3H]- naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-5’-hydroxymethylspiro[indoline-2,3’-[3H] - naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-9’-aminospiro[indoline-2,3’-[3H]- naphtho[2,1-b][1,4]oxazine]; 1,3,3-trimethyl-5-chloro-8’-hydroxyspiro[indoline-2,3’-[ 3H]- naphtho[2,1-b][1,4]oxazine]; 1-benzyl-3,3-dimethyl-9’-vinylbenzoyloxyspiro[indoline-2,3 ’- [3H]-naphtho[2,1-b][1,4]oxazine]; 1-benzyl-3,3-dimethyl-5’- hydroxymethylpiperidinospironaphthooxazine; 1,3,3-trimethyl-9’-hydroxyspiro[indoline- 2,3’-[3H]-pyrido-[2,1-b][1,4]benzooxazine]; 5-hydroxy-6’-cyano-1,3,3-trimethyl-spiro- [indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 5-hydroxy-6’-phenylsulfonyl-1,3,3- trimethyl-spiro-[indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxa zine]; 5’formyl-1,3,3- trimethylspiro[indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazi ne; 1,3-dihydro-6’-piperazino- 1,3,3-trimethyl spiro [2H indole-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine; 1,3-dihydro-6’-(4- hydroxyethyl)piperazino-1,3,3-trimethyl spiro [2H indole-2,3’-[3H]-naphtho[2,1- b][1,4]oxazine; 1,3-dihydro-9’-hydroxy-1,3,3-trimethyl spiro 92H indole-2,3’-[3H]- naphtho[2,1-b][1,4] oxazine; 1,3,3,4,5-pentamethyl-9’-methoxycarbonyl-8’-hydroxy- spiro[indoline-2,3’-[3H]naphth[2,1-b][1,4]oxazine; 1,3,3,5,6-pentamethyl-9’- methoxycarbonyl-8’-hydroxy-spiro[indoline-2,3’-[3H]napht h[2,1-b][1,4]oxazine; 1-propyl- 3,3,4,5-tetramethyl-9’-methoxycarbonyl-8’-hydroxy-spiro[ indoline-2,3’-[3H]naphth[2,1- b][1,4]oxazine; 1-propyl-3,3,5,6-tetramethyl-9’-methoxycarbonyl-8’-hydro xy- spiro[indoline-2,3’-[3H]naphth[2,1-b][1,4]oxazine; 1-methoxyethyl-3,3-dimethyl-9’- allyloxycarbonyl-8’-chloroactoxy-spiro[indoline-2,3’-[3H ]naphth[2,1-b][1,4]oxazine; 1- allyl-3,3-spirocyclohexyl-9’-benzyloxycarbonyl-8’-chloro actoxy-spiro[indoline-2,3’- [3H]naphth[2,1-b][1,4]oxazine; 5-amino-1,3,3-trimethyl-spiro[indoline-2,3’-[3H]- pyrido[3,4-f][1,4]benzoxazine; 6-hydroxy-1’,3’,3’,4’,5’-pentamethylspiro[2H-1,4- benzoxazine-2,2’-indoline]; 6-hydroxy-1’,3’,3’,5’,6’-pentamethylspiro[2H-1,4- benzoxazine-2,2’-indoline]; 5,7-dimethoxy-1’-hydroxy-carbonylethyl-3’,3’- dimethylspiro[2H-1,4-bezoxazine-2,2’-indoline]; 7-methoxy-1’-hydroxy-ethyl-3’,3’- dimethylspiro[2H-1,4-bezoxazine-2,2’-indoline]; 9’-hydroxy-1-methylspiro[indoline-2,3’- (3H)-naphtho(2,1-b)-1,4-oxazine]; 5-chloro-9’-hydroxy-1-methylspiro[indoline-2,3’-(3H)- naphtho(2,1-b)-1,4-oxazine]; 8’-hydroxy-1-methylspiro[indoline-2,3’-(3H)-naphtho(2,1- b)-1,4-oxazine]; 8’-hydroxy-5-methoxy-1-methylspiro[indoline-2,3’-(3H)-na phtho(2,1-b)- 1,4-oxazine]; 8’-hydroxy-1,4,5-trimethylspiro[indoline-2,3’-(3H)-napht ho(2,1-b)-1,4- oxazine]; 9’-hydroxy-1-isopropylspiro[indoline-2,3’-(3H)-naphtho(2 ,1-b)-1,4-oxazine]; 9’- hydroxy-1-hexadecyl-spiro[indoline-2,3’-(3H)-naphtho(2,1-b )-1,4-oxazine]; 9’-hydroxy-1- octadecylspiro[indoline-2,3’-(3H)-naphtho(2,1-b)-1,4-oxazi ne]; 1,1”-(1,5- pentanediyl)bis[3,3-dimethyl]-9’-hydroxy-spiro[indoline-2, 3’-[3H]-naphtho[2,1-b] [1,4]oxazine]; 1,1”-[1,4-phenylenebis(methylene)] bis[3,3-dimethyl]-5’- hydroxymethylspiro[indoline-2,3’-[3H]-naphtho[2,1-b] [1,4]oxazine]; 1,1”-(1,4- butanediyl)bis[5,6-dichloro-3,3-dimethyl]-8’-hydroxyspiro[ indoline-2,3’-[3H]-naphtho[2,1- b] [1,4]oxazine]; 1,3,3-trimethyl-9’-hydroxypiperidinospironaphthooxazine; 3- carboxyethyl-1,1-dimethyl-9’-methoxyspiro[benz[e]-indoline -2,3’-[3H]-naphtho[2,1- b][1,4]oxazine]; 1-carboxyethyl-3,3-dimethyl-9’-methoxyspiro[benz[g]-indoli ne-2,3’-[3H]- naphtho[2,1-b][1,4]oxazine]; 1,1-dimethyl-3-hydroxyethyl-9’-methoxyspiro[benz[e]- indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 3,3-dimethyl-1-hydroxyethyl-9’- methoxyspiro[benz[g]-indoline-2,3’-[3H]-naphtho[2,1-b][1,4 ]oxazine]; 3-carboxyethyl-1,1- dimethyl-9’-methoxyspiro[benz[e]-indoline-2,3’-[3H]-pyri do[2,1-b][1,4]benzoxazine]; 1- carboxyethyl-3,3-dimethyl-9’-methoxyspiro[benz[g]-indoline -2,3’-[3H]-pyrido[2,1- b][1,4]benzoxazine]; 1,1-dimethyl-3-hydroxyethyl-9’-methoxyspiro[benz[e]-indoli ne-2,3’- [3H]-pyrido[2,1-b][1,4]benzoxazine]; 3,3-dimethyl-1-hydroxyethyl-9’- methoxyspiro[benz[g]-indoline-2,3’-[3H]-pyrido[2,1-b][1,4] benzoxazine]; 5-amino-5’-(2- benzthiazolyl)-1,3,3-trimethylspiro[indoline-2,3’-[3H]-nap htho[2,1-b][1,4]oxazine]; 5- amino-5’-(5’-(2-hydroxyphenyl)-2-oxadiazolyl)-1-isopropy l-3,3-dimethylspiro[indoline- 2,3’-[3H]-naphtho[2,1-b][1,4]oxazine]; 5-amino-5’-(5’-phenyl-2-oxadiazolyl)-1,3,3- trimethylspiro[indoline-2,3’-[3H]-naphtho[2,1-b][1,4]oxazi ne]; or a mixture thereof. 63. The method of embodiment 58 or 59, wherein the reactive photochromic compound is 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxyethoxy-13-p henyl-3H,13H-indeno [2’,3’:3,4]naphtho[1,2-b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-(2- hydroxycarbonylethyl)carboxyethoxy-13-phenyl-3H,13H-indeno [2’,3’:3,4]naphtho[1,2- b]pyran; 3,3-bis(4-methoxyphenyl)-6,11-dimethyl-13-hydroxy-13-phenyl- 3H,13H-indeno [2’,3’:3,4]naphtho[1,2-b]pyran; or a mixture thereof. 64. The method of any one of embodiments 1 to 63, wherein said at least one first and second polymerizable materials independent of each other comprises at least one polymerizable UV/HEVL-absorbing compound. 65. The method of any one of embodiments 1 to 64, wherein the first polymerizable fluid composition further comprises at least one visible light free-radical photoinitiator, wherein the drop of the first polymerizable fluid composition is irradiated with a visible light for about 10 second or less before dispensing the second polymerizable fluid composition. 66. The method of embodiment 65, wherein said at least one visible light free radical photoinitiator comprises a benzoylphosphine initiator and/or an acylgermanium photoinitiator. 67. The method of embodiment 65, wherein said at least one first free radical photoinitiator comprises an acylgermanium photoinitiator that is 68. The method of embodiment 66 or 67, wherein the visible light is a visible light in a region of from 420 nm to 500 nm. 69. The method of any one of embodiments 65 to 68, wherein the drop of the first polymerizable fluid composition is irradiated with a visible light for about 8 second or less. 70. The method of any one of embodiments 65 to 68, wherein the drop of the first polymerizable fluid composition is irradiated with a visible light for about 5 second or less. 71. A hydrogel contact lens obtained according to the method of any one of embodiments 1 to 70. The previous disclosure will enable one having ordinary skill in the art to practice the invention. Various modifications, variations, and combinations can be made to the various embodiment described herein. In order to better enable the reader to understand specific embodiments and the advantages thereof, reference to the following examples is suggested. It is intended that the specification and examples be considered as exemplary. Example 1 Oxygen Permeability Measurements Unless specified, the oxygen transmissibility (Dk /t), the intrinsic (or edge-corrected) oxygen permeability (Dk i or Dk c ) of a lens and a lens material are determined according to procedures described in ISO 18369-4. Equilibrium Water Content The equilibrium water content (EWC) of contact lenses are determined as follows. Amount of water (expressed as percent by weight) present in a hydrated hydrogel contact lens, which is fully equilibrated in saline solution, is determined at room temperature. Quickly stack the lenses, and transfer the lens stack to the aluminum pan on the analytical balance after blotting lens in a cloth. The number of lenses for each sample pan is typically five (5). Record the pan plus hydrated weight of the lenses. Cover the pan with aluminum foil. Place pans in a laboratory oven at 100±2 °C to dry for 16-18 hours. Remove pan plus lenses from the oven and cool in a desiccator for at least 30 minutes. Remove a single pan from the desiccator, and discard the aluminum foil. Weigh the pan plus dried lens sample on an analytical balance. Repeat for all pans. The wet and dry weight of the lens samples can be calculated by subtracting the weight of the empty weigh pan. Elastic Modulus The elastic modulus of a contact lens is determined using a MTS insight instrument. The contact lens is first cut into a 3.12 mm wide strip using Precision Concept two stage cutter. Five thickness values are measured within 6.5mm gauge length. The strip is mounted on the instrument grips and submerged in PBS (phosphate buffered saline) with the temperature controlled at 21 ± 2 °C. Typically 5N Load cell is used for the test. Constant force and speed is applied to the sample until the sample breaks. Force and displacement data are collected by the TestWorks software. The elastic modulus value is calculated by the TestWorks software which is the slope or tangent of the stress vs. strain curve near zero elongation, in the elastic deformation region. Chemicals PrOH represent 1-propanol; TAA represents tert-amyl alcohol; EtOAc represents ethyl acetate; DMA represents N,N-dimethylacrylamide; MMA represents methyl methacrylate; EGMA represents ethylene glycol methyl ether methacrylate; TEGDMA represent triethyleneglycol dimethacrylate; D6 represents monobutyl-terminated monomethacryloxypropyl-terminated polydimethylsiloxane (Mw ~ 750 g/mol g/mol from Shin- Etsu); GA represents a hydrophilized polysiloxane vinylic crosslinker of formula (G) (Mn ~ 6.8K g/mol, OH content ~ 1.2 meq/g from Shin-Etsu); “G4” macromer represents a di- methacryloyloxypropyl-terminated polysiloxane (Mn ~ 13.5K g/mol, OH content ~ 1.8 meq/g) of formula (A) shown above; Vazo 64 represents 2,2'-dimethyl-2,2'azodipropiononitrile; Nobloc is 2-[3-(2H-Benzotriazol-2-yl)-4-hydroxyphenyl]ethyl methacrylate from Aldrich; Norbloc is 2-[2'-hydroxy-5'-(2-methacryloxyethyl)phenyl)]-2H-benzotriaz ole from Aldrich; NPD-blue represent a polymerizable naphthopyran photochromic dye having a blue color in activated state (from Vivimed); NPD-green represetns a polymerizable naphthopyran photochromic dye having a green color in activated state (from Vivimed); RB247 is Reactive Blue 247. Polymerizable Compositions Two polymerizable compositions for forming silicone hydrogel materials are prepared by blending all the required components to have the compositions shown in Tables 1 and 2. Table 1 Table 2 Fabrication of SiHy contact lens with a central photochromic zone Formulation 2A is purged with nitrogen at room temperature for 30 to 35 minutes. ~ 3 µL of Formulation 2A is dosed to the geometrical center of the molding surface of a male (BC) mold half (made of polypropylene) of a plastic mold (power: -3.0) to form a drop in the geometrical center of the molding surface of the male mold half. Formulation 2B is purged with nitrogen at room temperature for 30 to 35 minutes. ~60 µL of N 2 -purged Formulation 2B is added onto the molding surface of the female (FC) mold half and then the mold is closed with the male (BC) mold half having the drop adhered thereon to form a molding assembly comprising Formulation 2B and the drop of the Formulation 2A. The molding assembly is thermally cured in an oven under the following curing profile: ramp from room temperature to 55°C at a ramp rate of about 7°C/minute; holding at 55°C for about 30 minutes; ramp from 55°C to 80°C at a ramp rate of about 7°C/minute; holding at 80°C for about 30 minutes; ramp from 80°C to 100°C at a ramp rate of about 7°C/minute; and holding at 100°C for about 30 minutes. After de-molding, cast-molded SiHy contact lenses are extracted with PrOH for 180 minutes and then rinsed in PB (phosphate buffer containing about 0.077 wt.% NaH 2 PO 4 ·H 2 O and about 0.31 wt.% Na 2 HPO 4 ·2H 2 O) for 1 hour. All the publications and patents which have been cited herein above are hereby incorporated by reference in their entireties.
Next Patent: SYSTEM AND METHOD FOR TRANSLATION OF STREAMING ENCRYPTED CONTENT